<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0103-4014</journal-id>
<journal-title><![CDATA[Estudos Avançados]]></journal-title>
<abbrev-journal-title><![CDATA[Estud. av.]]></abbrev-journal-title>
<issn>0103-4014</issn>
<publisher>
<publisher-name><![CDATA[Instituto de Estudos Avançados da Universidade de São Paulo]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0103-40142010000300004</article-id>
<article-id pub-id-type="doi">10.1590/S0103-40142010000300004</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Terapia gênica: o que é, o que não é e o que será]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Linden]]></surname>
<given-names><![CDATA[Rafael]]></given-names>
</name>
</contrib>
</contrib-group>
<aff id="A">
<institution><![CDATA[,  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2010</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2010</year>
</pub-date>
<volume>24</volume>
<numero>70</numero>
<fpage>31</fpage>
<lpage>69</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0103-40142010000300004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.br/scielo.php?script=sci_abstract&amp;pid=S0103-40142010000300004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.br/scielo.php?script=sci_pdf&amp;pid=S0103-40142010000300004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Terapia gênica é o tratamento baseado na introdução de genes sadios com uso de técnicas de DNA recombinante. O primeiro teste clínico bem-sucedido dessa técnica foi divulgado em 1990. Em que pese a ocorrência, em certos estudos clínicos, de efeitos adversos, alguns dos quais graves, laboratórios de pesquisa e empresas vêm continuamente desenvolvendo novos materiais e procedimentos mais seguros e eficazes. Embora ainda em estágio experimental, progressos recentes indicam oportunidades crescentes de investimento pela indústria, bem como justificam a expectativa de que, em alguns casos, essa tecnologia poderá chegar à prática clínica dentro de poucos anos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Gene therapy is the therapeutic procedure based on the introduction of healthy genes using recombinant DNA techniques. The first successful clinical trial of this technique was published in 1990. Despite the occurrence, in certain clinical trials, of adverse effects, some of which serious, both laboratories and companies are continuously developing novel materials and establishing both safer and more effective procedures. Although still in experimental stages, recent progress both points to growing opportunities for investment by industry, as well as justify the expectation that, in some cases, this technology may reach clinical practice within a few years.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Genes]]></kwd>
<kwd lng="pt"><![CDATA[Doenças genéticas]]></kwd>
<kwd lng="pt"><![CDATA[Engenharia genética]]></kwd>
<kwd lng="pt"><![CDATA[Manipulação do genoma]]></kwd>
<kwd lng="pt"><![CDATA[Terapias avançadas]]></kwd>
<kwd lng="pt"><![CDATA[Biotecnologia]]></kwd>
<kwd lng="en"><![CDATA[Genes]]></kwd>
<kwd lng="en"><![CDATA[Genetic diseases]]></kwd>
<kwd lng="en"><![CDATA[Genetic engineering]]></kwd>
<kwd lng="en"><![CDATA[Genome manipulation]]></kwd>
<kwd lng="en"><![CDATA[Advanced therapies]]></kwd>
<kwd lng="en"><![CDATA[Biotechnology]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2" face="Verdana"><b>DOSSI&Ecirc; BIOTECNOLOGIA</b></font></p>     <p>&nbsp;</p>     <p><font size="4" face="verdana"><b>Terapia g&ecirc;nica: o que &eacute;, o que n&atilde;o &eacute; e o que ser&aacute; </b></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><b>Rafael Linden</b></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p> <hr size="1" noshade>     <p><font size="2" face="VERDANA"><b>RESUMO</b></font></p>     <p><font size="2" face="Verdana">Terapia g&ecirc;nica &eacute; o tratamento baseado na introdu&ccedil;&atilde;o de genes sadios com uso de t&eacute;cnicas de DNA recombinante. O primeiro teste cl&iacute;nico bem&#45;sucedido dessa t&eacute;cnica foi divulgado em 1990. Em que pese a ocorr&ecirc;ncia, em certos estudos cl&iacute;nicos, de efeitos adversos, alguns dos quais graves, laborat&oacute;rios de pesquisa e empresas v&ecirc;m continuamente desenvolvendo novos materiais e procedimentos mais seguros e eficazes. Embora ainda em est&aacute;gio experimental, progressos recentes indicam oportunidades crescentes de investimento pela ind&uacute;stria, bem como justificam a expectativa de que, em alguns casos, essa tecnologia poder&aacute; chegar &agrave; pr&aacute;tica cl&iacute;nica dentro de poucos anos.</font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"><b>Palavras&#45;chave:</b> Genes, Doen&ccedil;as gen&eacute;ticas, Engenharia gen&eacute;tica, Manipula&ccedil;&atilde;o do genoma, Terapias avan&ccedil;adas, Biotecnologia.</font></p> <hr size="1" noshade>     <p><font size="2" face="Verdana"><b>ABSTRACT</b></font></p>     <p><font size="2" face="Verdana"> Gene therapy is the therapeutic procedure based on the introduction of healthy genes using recombinant DNA techniques. The first successful clinical trial of this technique was published in 1990. Despite the occurrence, in certain clinical trials,  of adverse effects, some of which serious, both laboratories and companies are continuously developing novel materials and establishing both safer and more effective procedures. Although still in experimental stages, recent progress both points to growing opportunities for investment by industry, as well as justify the expectation that, in some cases, this technology may reach clinical practice within a few years.</font></p>     <p><font size="2" face="Verdana"><b>Keywords:</b> Genes, Genetic diseases, Genetic engineering, Genome manipulation, Advanced therapies, Biotechnology.</font></p> <hr size="1" noshade>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     <p><font size="2" face="Verdana">DESDE sua funda&ccedil;&atilde;o, pelo monge Johann (Gregor) Mendel no s&eacute;culo XIX, aos dias de hoje, a gen&eacute;tica evoluiu extraordinariamente e conquistou um lugar de destaque entre as ci&ecirc;ncias. H&aacute; dez anos foi completado o sequenciamento do genoma humano (Lander et al., 2001; Venter et al., 2001), um feito grandioso que promete acelerar o progresso da biologia e da medicina do s&eacute;culo XXI. </font></p>     <p><font size="2" face="Verdana">A medicina moderna acrescenta, a cada dia, descobertas importantes em &aacute;reas de investiga&ccedil;&atilde;o destinadas ao desenvolvimento de novos paradigmas de tratamento para doen&ccedil;as ainda incur&aacute;veis. Entre elas, a expectativa de curar doen&ccedil;as gen&eacute;ticas repousa sobre a identifica&ccedil;&atilde;o de genes respons&aacute;veis por sua patog&ecirc;nese e sobre o avan&ccedil;o das tecnologias de DNA recombinante, ou "engenharia gen&eacute;tica", que permitem a manipula&ccedil;&atilde;o do genoma de forma cada vez mais eficiente e segura (Watson et al., 2006). Em paralelo, a determina&ccedil;&atilde;o de fatores gen&eacute;ticos de suscetibilidade a certas doen&ccedil;as, seu curso e suas manifesta&ccedil;&otilde;es cl&iacute;nicas (NCBI, 2009), bem como o enorme avan&ccedil;o na compreens&atilde;o da biologia celular e molecular de eventos patol&oacute;gicos fundamentais, tais como processos inflamat&oacute;rios, dist&uacute;rbios de prolifera&ccedil;&atilde;o e morte celular programada (Coleman &amp; Tsongalis, 2009), aumentam a expectativa de que a manipula&ccedil;&atilde;o do genoma possa vir a ser aplicada a uma ampla gama de doen&ccedil;as.</font></p>     <p><font size="2" face="Verdana">Essa &eacute; uma &aacute;rea ainda incipiente da medicina, praticada especialmente nos laborat&oacute;rios de pesquisa fundamental, e sua aplica&ccedil;&atilde;o ainda &eacute; estritamente experimental. J&aacute; h&aacute; nessa &aacute;rea produtos comerciais aprovados para uso m&eacute;dico (Pearson et al., 2004), mas a expectativa dos cientistas, bem como da ind&uacute;stria farmac&ecirc;utica e de biotecnologia, &eacute; de que a libera&ccedil;&atilde;o de protocolos de manipula&ccedil;&atilde;o do genoma para a pr&aacute;tica m&eacute;dica e o respectivo mercado de biol&oacute;gicos dever&atilde;o avan&ccedil;ar cautelosamente ao longo dos pr&oacute;ximos 5&#45;10 anos, ainda assim englobando um n&uacute;mero restrito de aplica&ccedil;&otilde;es.</font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">J&aacute; em 1990, entretanto, uma equipe m&eacute;dica norte&#45;americana tinha inserido um gene sadio no organismo de uma menina doente e a crian&ccedil;a melhorou ap&oacute;s esse tratamento. Come&ccedil;ara uma nova era. A era da terapia g&ecirc;nica (ou terapia gen&eacute;tica), ou seja, o procedimento destinado a introduzir em um organismo, com o uso de t&eacute;cnicas de DNA recombinante, genes sadios (nesse contexto denominados "genes terap&ecirc;uticos") para substituir, manipular ou suplementar genes inativos ou disfuncionais (Linden, 2008).</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Prim&oacute;rdios da terapia g&ecirc;nica</b></font></p>     <p><font size="2" face="Verdana">A partir da d&eacute;cada de 1940, a gen&eacute;tica tomou grande impulso, e descobertas sobre a natureza, composi&ccedil;&atilde;o qu&iacute;mica e as propriedades do material gen&eacute;tico, bem como as primeiras manipula&ccedil;&otilde;es do DNA de bact&eacute;rias, come&ccedil;aram a gerar expectativas de novos avan&ccedil;os terap&ecirc;uticos.</font></p>     <p><font size="2" face="Verdana">Em meados da d&eacute;cada de 1960, come&ccedil;ou a especula&ccedil;&atilde;o sobre a possibilidade de utilizar v&iacute;rus para transferir genes a seres humanos doentes e curar doen&ccedil;as gen&eacute;ticas (Friedmann, 1997). J&aacute; naquela &eacute;poca, considerava&#45;se tanto que os pr&oacute;prios genes de certos v&iacute;rus pudessem fazer efeito quanto que fosse poss&iacute;vel inserir genes humanos sadios em v&iacute;rus para que esses os transferissem ao paciente. Entretanto, foi s&oacute; no in&iacute;cio da d&eacute;cada seguinte que Paul Berg conseguiu de fato manipular uma mol&eacute;cula de DNA (Jackson et al., 1972), criando a tecnologia do DNA recombinante. </font></p>     <p><font size="2" face="Verdana">Duas tentativas iniciais de aplicar na pr&aacute;tica cl&iacute;nica o conceito de terapia g&ecirc;nica fracassaram, uma delas por se apoiar em uma premissa sobre propriedades de um v&iacute;rus, a qual, mais tarde, se mostrou falsa (Rogers, 1952; Rogers &amp; Rous, 1951; Andrewes, 1966; Friedman, 2001; Scaglia &amp; Lee, 2006); outra, embora tecnicamente justific&aacute;vel e j&aacute; utilizando metodologias de DNA recombinante, foi maculada por grave deslize &eacute;tico (Mercola &amp; Cline, 1980). Mas, em 1989, um novo teste, feito de acordo com as regras vigentes na &eacute;poca, restabeleceu expectativas positivas nessa &aacute;rea de pesquisa. </font></p>     <p><font size="2" face="Verdana">A paciente tratada em 1989 era uma menina de quatro anos de idade incapaz de levar uma vida normal, porque sofria de uma doen&ccedil;a gen&eacute;tica causada por defici&ecirc;ncia da enzima adenosina desaminase (ADA), indispens&aacute;vel para o desenvolvimento do sistema imune. V&aacute;rias muta&ccedil;&otilde;es no gene que codifica a enzima provocam defici&ecirc;ncia de ADA, o que resulta em degenera&ccedil;&atilde;o das c&eacute;lulas T do sistema imune (Buckley, 2004) e constitui uma das principais causas de s&iacute;ndrome de imunodefici&ecirc;ncia combinada severa (SCID, do ingl&ecirc;s <I>severe combined immunodeficiency</I>). No caso em quest&atilde;o, a doen&ccedil;a &eacute; conhecida pela sigla SCID&#45;ADA. Crian&ccedil;as afetadas pelas diversas formas de SCID (ibidem) t&ecirc;m baix&iacute;ssima resist&ecirc;ncia a infec&ccedil;&otilde;es e, se n&atilde;o forem tratadas, morrem em geral antes dos seis meses de idade. S&atilde;o conhecidas como "crian&ccedil;as da bolha", por necessitarem de isolamento feito, frequentemente, por meio de compartimentos de pl&aacute;stico transparente. O tratamento &eacute; usualmente feito por reposi&ccedil;&atilde;o da enzima atrav&eacute;s de inje&ccedil;&otilde;es semanais. Naquele caso, depois de um per&iacute;odo de um ano em que houve relativo sucesso, no segundo ano de tratamento a crian&ccedil;a voltou a sofrer infec&ccedil;&otilde;es frequentes e desenvolveu uma alergia ao preparado da enzima usado para inje&ccedil;&otilde;es. Os ind&iacute;cios eram de que a terapia de reposi&ccedil;&atilde;o enzim&aacute;tica estava falhando. O m&eacute;dico William French Anderson, da Universidade do Sul da Calif&oacute;rnia, obteve ent&atilde;o autoriza&ccedil;&atilde;o dos comit&ecirc;s de &eacute;tica para iniciar um teste de terapia g&ecirc;nica (Anderson et al., 1990).</font></p>     <p><font size="2" face="Verdana">A cada um ou dois meses, os pesquisadores retiravam c&eacute;lulas T do sangue de Ashanti, inseriam o gene da ADA, induziam a prolifera&ccedil;&atilde;o dessas c&eacute;lulas no laborat&oacute;rio e, ent&atilde;o, devolviam as c&eacute;lulas tratadas para o sangue da paciente (Culver et al., 1991). Depois de sete infus&otilde;es, houve uma pausa de seis meses, e, a partir da&iacute;, as infus&otilde;es recome&ccedil;aram at&eacute; o tratamento completar dois anos. Por seguran&ccedil;a, a menina continuou a receber as inje&ccedil;&otilde;es semanais da enzima. A terapia g&ecirc;nica dessa paciente, bem como a realizada a partir de 1991 em uma segunda paciente de nove anos de idade, teve resultados positivos. Houve melhora cl&iacute;nica com uma redu&ccedil;&atilde;o da quantidade de enzima que era necess&aacute;rio repor. Observou&#45;se que os n&iacute;veis da enzima no sangue das pacientes aumentaram progressivamente com a terapia g&ecirc;nica e se mantiveram est&aacute;veis no intervalo de descanso de seis meses (Blaese et al., 1995; Mullen et al., 1996). Finalmente, doze anos ap&oacute;s terminarem as infus&otilde;es, &eacute;poca em que foi feita uma reavalia&ccedil;&atilde;o dos dois casos, grandes n&uacute;meros de c&eacute;lulas T continuaram expressando o gene terap&ecirc;utico no sangue da primeira paciente, cujo tratamento foi mais bem&#45;sucedido do que o da segunda (Muul et al., 2003).</font></p>     <p><font size="2" face="Verdana">Deve&#45;se assinalar que ainda h&aacute; quest&otilde;es t&eacute;cnicas relacionadas a esse estudo, que n&atilde;o permitem consider&aacute;&#45;lo um completo sucesso cl&iacute;nico. Como as crian&ccedil;as continuaram a receber reposi&ccedil;&atilde;o da enzima, embora em doses menores, h&aacute; d&uacute;vida sobre o quanto a terapia g&ecirc;nica ter&aacute; de fato contribu&iacute;do para que, por exemplo, a primeira paciente esteja hoje, aos 24 anos de idade, saud&aacute;vel e ativa. No entanto, a partir das observa&ccedil;&otilde;es feitas ao longo do tratamento dessas duas primeiras pacientes, a terapia g&ecirc;nica para SCID&#45;ADA evoluiu e hoje &eacute; considerada um sucesso cl&iacute;nico (Aiuti et al., 2009; Kohn &amp; Candotti, 2009). Mesmo incipiente, o estudo iniciado em 1989, que obteve pelo menos alguns resultados positivos observando os requisitos &eacute;ticos, &eacute; um marco na hist&oacute;ria da terapia g&ecirc;nica e inspirou o crescimento subsequente dessa &aacute;rea de investiga&ccedil;&atilde;o cient&iacute;fica.</font></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font size="3" face="Verdana"><b>Modalidades de terapia g&ecirc;nica</b></font></p>     <p><font size="2" face="Verdana">A ideia de usar as t&eacute;cnicas de DNA recombinante para corrigir o genoma foi inspirada nas doen&ccedil;as causadas por muta&ccedil;&atilde;o em um &uacute;nico gene (ditas doen&ccedil;as monog&ecirc;nicas). Nesse caso, a ideia &eacute; substituir ou suplementar a express&atilde;o do gene disfuncional, mediante a inser&ccedil;&atilde;o de uma ou mais c&oacute;pias do gene terap&ecirc;utico (Porteus et al., 2006; O'Connor &amp; Crystal, 2006; Brinkman et al., 2006). O tratamento da SCID&#45;ADA representa uma aplica&ccedil;&atilde;o bem&#45;sucedida dessa ideia. </font></p>     <p><font size="2" face="Verdana">Mas as doen&ccedil;as monog&ecirc;nicas n&atilde;o s&atilde;o o &uacute;nico alvo da terapia g&ecirc;nica (<a href="#fig01">Figura 1</a>). A medicina moderna luta contra muitas doen&ccedil;as complexas, cujas causas prim&aacute;rias ainda n&atilde;o s&atilde;o conhecidas e para as quais h&aacute;, na melhor das hip&oacute;teses, apenas tratamentos paliativos. Em certos casos, &eacute; poss&iacute;vel planejar uma interven&ccedil;&atilde;o por meio de terapia g&ecirc;nica, visando reduzir ou evitar a progress&atilde;o da doen&ccedil;a. A interven&ccedil;&atilde;o pode ser baseada no conhecimento de determinantes gen&eacute;ticos de suscetibilidade ou gravidade, ou na oportunidade de alterar mecanismos fundamentais ou a fisiologia das c&eacute;lulas, dos &oacute;rg&atilde;os ou sistemas afetados pelas doen&ccedil;as (Cardone, 2007; Flotte, 2007). As principais estrat&eacute;gias s&atilde;o aumentar a resist&ecirc;ncia celular, estimular sistemas de reparo ou regenera&ccedil;&atilde;o, ou ainda recompor caracter&iacute;sticas funcionais espec&iacute;ficas de determinados sistemas org&acirc;nicos, mediante modula&ccedil;&atilde;o de genes n&atilde;o necessariamente associados &agrave; causa da doen&ccedil;a (Bagley et al., 2008; Lundberg et al., 2008). J&aacute; no caso de tumores, o principal objetivo &eacute; a indu&ccedil;&atilde;o de morte celular seletiva em popula&ccedil;&otilde;es celulares proliferativas (Bauzon &amp; Hermiston, 2008; Cattaneo et al., 2008; Ribacka et al., 2008).</font></p>     <p><a name="fig01"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig01.jpg"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana">Finalmente, h&aacute; uma forma peculiar de terapia g&ecirc;nica denominada vacina de DNA. Nessa, ao inv&eacute;s da utiliza&ccedil;&atilde;o de uma prote&iacute;na ou um v&iacute;rus completo inativado, como se faz nas vacinas convencionais, o paciente recebe o gene que codifica uma prote&iacute;na t&iacute;pica do agente agressor. Dessa forma, o organismo do paciente passar&aacute; a fabricar permanentemente a prote&iacute;na ex&oacute;gena, estimulando seu pr&oacute;prio sistema imune. Essas vacinas podem ter finalidade preventiva, de forma semelhante &agrave;s vacinas cl&aacute;ssicas, ou curativa, levando o sistema imune a atacar os agentes agressores j&aacute; instalados no organismo (Atkins et al., 2008, Sykes, 2008; Silva et al., 2009).</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Terapia celular, c&eacute;lulas&#45;tronco e terapia g&ecirc;nica </b></font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">As c&eacute;lulas&#45;tronco s&atilde;o, atualmente, o principal assunto de natureza m&eacute;dica na m&iacute;dia. Ao mesmo tempo, criou&#45;se certa confus&atilde;o entre c&eacute;lulas&#45;tronco, terapias celulares e terapias gen&eacute;ticas. Nas chamadas terapias celulares, empregam&#45;se c&eacute;lulas inteiras para tratar uma doen&ccedil;a, com base nas propriedades regenerativas de c&eacute;lulas&#45;tronco ou em outros efeitos, a maior parte dos quais ainda n&atilde;o explicados, das c&eacute;lulas transplantadas. O exemplo cl&aacute;ssico, cuja fundamenta&ccedil;&atilde;o &eacute; bem conhecida, &eacute; o de leucemias, mas h&aacute; expectativa de que muitas classes de doen&ccedil;as possam vir a ser tratadas com emprego de terapias celulares nos pr&oacute;ximos anos (Torrente &amp; Polli, 2008; Gribben, 2008; Einstein &amp; Ben&#45;Hur, 2008; Reffelmann et al., 2008). </font></p>     <p><font size="2" face="Verdana">No presente contexto, &eacute; importante frisar que terapias celulares n&atilde;o envolvem necessariamente modifica&ccedil;&atilde;o gen&eacute;tica. J&aacute; as terapias g&ecirc;nicas s&atilde;o baseadas na introdu&ccedil;&atilde;o ou modifica&ccedil;&atilde;o de genes. Isso pode ser feito diretamente <I>in vivo</I>, sem o aux&iacute;lio de c&eacute;lulas inteiras do pr&oacute;prio paciente ou de doadores. </font></p>     <p><font size="2" face="Verdana">Ou seja, terapia g&ecirc;nica e terapia celular s&atilde;o dois conceitos distintos. Entretanto, h&aacute; m&eacute;todos que combinam as duas t&eacute;cnicas. Um exemplo de combina&ccedil;&atilde;o de terapia g&ecirc;nica com terapia celular foi, novamente, o procedimento <I>ex vivo</I> que inaugurou a terapia g&ecirc;nica, e que foi descrito antes. Novas tecnologias de terapia g&ecirc;nica para a SCID&#45;ADA s&atilde;o baseadas na manipula&ccedil;&atilde;o gen&eacute;tica de c&eacute;lulas&#45;tronco de medula &oacute;ssea, em lugar das c&eacute;lulas T empregadas nos primeiros estudos (Aiuti et al., 2009). Portanto, em certas circunst&acirc;ncias, podem&#45;se utilizar c&eacute;lulas como ve&iacute;culo para introduzir o gene terap&ecirc;utico. Mas s&atilde;o a introdu&ccedil;&atilde;o do gene e o uso das tecnologias de DNA recombinante que caracterizam o tratamento como terapia g&ecirc;nica. </font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Vetores para terapia g&ecirc;nica</b></font></p>     <p><font size="2" face="Verdana">A base da terapia g&ecirc;nica consiste na introdu&ccedil;&atilde;o de genes em c&eacute;lulas. Por&eacute;m, a entrada de DNA puro atrav&eacute;s da membrana plasm&aacute;tica de c&eacute;lulas eucari&oacute;ticas &eacute; extremamente rara (Vellai &amp; Vida, 1999). Essa dificuldade &eacute;, naturalmente, ben&eacute;fica para o organismo, pois dificulta altera&ccedil;&otilde;es esp&uacute;rias do metabolismo celular e at&eacute; mesmo transforma&ccedil;&otilde;es semelhantes &agrave;s que se observam na evolu&ccedil;&atilde;o das esp&eacute;cies. </font></p>     <p><font size="2" face="Verdana">Por conseguinte, de modo geral, h&aacute; necessidade de um carreador que facilite a entrada do DNA nas c&eacute;lulas vivas. Esse ve&iacute;culo &eacute; denominado "vetor". H&aacute; tr&ecirc;s classes principais de vetores atualmente em desenvolvimento: plasm&iacute;deos, vetores virais e vetores nanoestruturados.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Plasm&iacute;deos</b></font></p>     <p><font size="2" face="Verdana">Os plasm&iacute;deos s&atilde;o sequ&ecirc;ncias de DNA relativamente simples, por&eacute;m eficazes para express&atilde;o de genes, nas quais &eacute; poss&iacute;vel inserir um gene terap&ecirc;utico por t&eacute;cnicas de DNA recombinante (Voss, 2007; Clanchy &amp; Williams, 2008; Gill et al., 2009). Mas, para vencer a resist&ecirc;ncia das c&eacute;lulas &agrave; introdu&ccedil;&atilde;o de plasm&iacute;&#45;deos, &eacute; preciso fragilizar a membrana celular, o que pode ser obtido por diversos m&eacute;todos, como o emprego de choques el&eacute;tricos ou subst&acirc;ncias que fragilizam quimicamente a membrana celular (Dass, 2004; Cemazar &amp; Sersa, 2007; Favard et al., 2007; Wu &amp; Lu, 2007). Outra alternativa consiste em aplicar uma grande quantidade de plasm&iacute;deos nas vizinhan&ccedil;as das c&eacute;lulas, de modo que, mesmo com efici&ecirc;ncia muito baixa, uma pequena fra&ccedil;&atilde;o que seja capaz de cruzar a membrana j&aacute; produza efeitos, ou ainda injetar rapidamente um grande volume de solu&ccedil;&atilde;o contendo plasm&iacute;deos (Herweijer &amp; Wolff, 2007).</font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">Essas t&eacute;cnicas s&atilde;o, entretanto, muito limitadas. Por exemplo, &eacute; improv&aacute;vel seu uso para introduzir genes em &oacute;rg&atilde;os de dif&iacute;cil acesso, como o c&eacute;rebro. Assim, o emprego de vetores plasmidiais &eacute; limitado a algumas circunst&acirc;ncias, tais como sua introdu&ccedil;&atilde;o por inje&ccedil;&atilde;o intramuscular, como no caso das vacinas de DNA ou no m&uacute;sculo card&iacute;aco, ou ainda em estudos experimentais em animais. Outrossim, essa tecnologia pode ter aplica&ccedil;&otilde;es importantes, por exemplo, para introduzir o gene sadio em c&eacute;lulas isoladas e combinar terapia g&ecirc;nica com terapia celular.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Vetores virais</b></font></p>     <p><font size="2" face="Verdana">Em contraposi&ccedil;&atilde;o &agrave; resist&ecirc;ncia da membrana celular &agrave; entrada espont&acirc;nea de DNA em uma c&eacute;lula, os v&iacute;rus s&atilde;o micro&#45;organismos especializados exatamente em invadir c&eacute;lulas e nelas introduzir material gen&eacute;tico. Cont&ecirc;m &aacute;cido nucleico (DNA ou RNA) cercado por uma capa de prote&iacute;na e, em alguns casos, de um envelope adicional de prote&iacute;na e lip&iacute;deos e seu ciclo de vida implica libera&ccedil;&atilde;o do &aacute;cido nucleico viral na c&eacute;lula hospedeira. Essa propriedade &eacute; explorada para introduzir genes terap&ecirc;uticos nas c&eacute;lulas, por meio de tecnologias de DNA recombinante.</font></p>     <p><font size="2" face="Verdana">Alguns vetores s&atilde;o derivados de adenov&iacute;rus. Essa fam&iacute;lia inclui quase 50 tipos distintos de v&iacute;rus que causam, por exemplo, faringites ou conjuntivites. Infec&ccedil;&otilde;es por adenov&iacute;rus s&atilde;o muito comuns, e, por isso, a maior parte da popula&ccedil;&atilde;o possui anticorpos contra um ou mais tipos dessa fam&iacute;lia de v&iacute;rus. Outros s&atilde;o da fam&iacute;lia dos retrov&iacute;rus, que inclui o HTLV causador de um tipo de leucemia e o HIV causador da Aids, que pertence &agrave; subfam&iacute;lia dos lentiv&iacute;rus, os quais v&ecirc;m sendo muito estudados como fonte de vetores para terapia g&ecirc;nica. Ainda outros vetores s&atilde;o derivados de v&iacute;rus da fam&iacute;lia dos adenov&iacute;rus&#45;associados, que n&atilde;o s&atilde;o patog&ecirc;nicos para seres humanos. </font></p>     <p><font size="2" face="Verdana">O princ&iacute;pio da produ&ccedil;&atilde;o de vetores de origem viral para terapia g&ecirc;nica (<a href="#fig02">figuras 2</a> e <a href="#fig03">3</a>) consiste em remover os genes envolvidos nos mecanismos patog&ecirc;nicos e de prolifera&ccedil;&atilde;o viral, mantendo apenas o necess&aacute;rio para invas&atilde;o das c&eacute;lulas sem multiplica&ccedil;&atilde;o, seguida da inser&ccedil;&atilde;o de um gene terap&ecirc;utico no que resta do DNA viral (Machida, 2002). A remo&ccedil;&atilde;o de genes que conferem o car&aacute;ter patog&ecirc;nico e a multiplica&ccedil;&atilde;o permite, por exemplo, que um v&iacute;rus da mesma subfam&iacute;lia do perigoso HIV possa dar origem a um vetor viral &uacute;til para terapia g&ecirc;nica.</font></p>     <p><a name="fig02"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig02.jpg"></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><a name="fig03"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig03.jpg"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana">Os vetores virais diferem entre si (<a href="#tab01">Tabela 1</a>). Uns s&atilde;o mais eficientes, outros t&ecirc;m maior capacidade de veicular genes grandes. Alguns t&ecirc;m maior propens&atilde;o a provocar rea&ccedil;&otilde;es inflamat&oacute;rias do que outros. Finalmente, alguns vetores, como os derivados de retrov&iacute;rus, t&ecirc;m a propriedade de se integrar ao genoma das c&eacute;lulas. Isso &eacute; positivo quando se quer uma express&atilde;o permanente do gene terap&ecirc;utico, mas pode causar efeitos adversos graves.</font></p>     <p><a name="tab01"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04tab01.jpg"></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Vetores nanoestruturados</b></font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">Outra forma de introduzir DNA em c&eacute;lulas est&aacute; sendo desenvolvida a partir de preparados obtidos por t&eacute;cnicas avan&ccedil;adas de nanotecnologia (Sanvicens &amp; Marco, 2008). A&iacute; se incluem pol&iacute;meros que formam verdadeiras redes que prendem um gene e soltam sua carga quando penetram nas c&eacute;lulas, bem como ves&iacute;culas de lip&iacute;deos contendo o DNA, capazes de fundir com a membrana das c&eacute;lulas, liberando seu conte&uacute;do no interior destas &uacute;ltimas.</font></p>     <p><font size="2" face="Verdana">Esses vetores podem ser enriquecidos com mol&eacute;culas que ajudem a especificar em que tipos de c&eacute;lulas o conte&uacute;do poder&aacute; penetrar, ou ainda permitam guiar ou transferir seletivamente os vetores de um compartimento para outro, por exemplo, do sangue para o c&eacute;rebro (Pardridge, 2005, 2007, <a href="#fig04">Figura 4</a>). Esta &uacute;ltima t&eacute;cnica &eacute; importante, pois facilitar&aacute; a terapia g&ecirc;nica cerebral sem a necessidade de uma neurocirurgia para introduzir o vetor, bastando inje&ccedil;&otilde;es endovenosas.</font></p>     <p><a name="fig04"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig04.jpg"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana">Ainda em outros casos, c&eacute;lulas modificadas pela introdu&ccedil;&atilde;o de um gene terap&ecirc;utico podem ser encapsuladas em compartimentos produzidos a partir de pol&iacute;meros inertes e, depois, introduzidas no organismo. A vantagem dessa t&eacute;cnica &eacute; que as c&eacute;lulas podem produzir e secretar mol&eacute;culas terap&ecirc;uticas enquanto ficam isoladas do sistema imune do paciente (Hauser et al., 2004; Lindvall &amp; Wahlberg, 2008). Portanto, as c&eacute;lulas encapsuladas n&atilde;o precisam ser derivadas do pr&oacute;prio paciente.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Terapia g&ecirc;nica hoje</b></font></p>     <p><font size="2" face="Verdana">As terapias g&ecirc;nicas s&atilde;o procedimentos novos que ainda se encontram em fase experimental. O conhecimento b&aacute;sico vem sendo adquirido em laborat&oacute;rios de pesquisa fundamental por meio de testes em modelos experimentais e ensaios pr&eacute;&#45;cl&iacute;nicos. Esses estudos validam o potencial de efic&aacute;cia de uma estrat&eacute;gia terap&ecirc;utica, bem como permitem detectar potenciais riscos a seres humanos, antecipando modifica&ccedil;&otilde;es dos vetores e outros componentes da estrat&eacute;gia terap&ecirc;utica que aumentem a seguran&ccedil;a para uso humano. </font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">A pesquisa fundamental em terapia g&ecirc;nica &eacute; intensa e crescente no mundo. A <a href="#fig05">Figura 5</a> ilustra o crescimento cont&iacute;nuo do volume de publica&ccedil;&otilde;es cient&iacute;ficas nessa &aacute;rea. Nos &uacute;ltimos tr&ecirc;s anos, foram publicados, em m&eacute;dia, cerca de 30 artigos cient&iacute;ficos sobre assuntos relacionados a terapia g&ecirc;nica <I>por dia</I>.</font></p>     <p><a name="fig05"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig05.jpg"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana">Como em outras &aacute;reas de investiga&ccedil;&atilde;o de novos m&eacute;todos terap&ecirc;uticos, a aprova&ccedil;&atilde;o de um produto ou processo de terapia g&ecirc;nica depende da realiza&ccedil;&atilde;o de uma s&eacute;rie de ensaios cl&iacute;nicos, que s&atilde;o classificados por fases. Inicia&#45;se pela chamada fase I, cujo objetivo &eacute; testar a seguran&ccedil;a do procedimento e identificar quaisquer efeitos adversos atribu&iacute;dos ao novo produto ou m&eacute;todo. Seguem&#45;se ensaios de fase II, III e IV que, progressivamente e sempre acompanhados de vigil&acirc;ncia quanto a efeitos adversos, destinam&#45;se a testar a efic&aacute;cia do novo produto ou m&eacute;todo em amostras crescentes de pacientes, frequentemente distribu&iacute;dos em m&uacute;ltiplos centros de pesquisa. </font></p>     <p><font size="2" face="Verdana">A realiza&ccedil;&atilde;o desses ensaios cl&iacute;nicos de terapia g&ecirc;nica depende de aprova&ccedil;&atilde;o pr&eacute;via por comit&ecirc;s de &eacute;tica locais e nacionais, como a Comiss&atilde;o Nacional de &Eacute;tica em Pesquisa (Conep) no Brasil ou a Food and Drug Administration (FDA) nos Estados Unidos. No caso de terapia g&ecirc;nica, existe ainda no Brasil a Comiss&atilde;o T&eacute;cnica Nacional de Biosseguran&ccedil;a (CTNBio) e nos Estados Unidos um comit&ecirc; espec&iacute;fico do Instituto Nacional de Sa&uacute;de (NIH, do ingl&ecirc;s National Institutes of Health), chamado RAC (do ingl&ecirc;s Recombinant DNA Advisory Committee), que devem autorizar procedimentos envolvendo DNA recombinante. No entanto, diferentemente dos Estados Unidos, ainda n&atilde;o existe no Brasil regulamenta&ccedil;&atilde;o espec&iacute;fica sobre terapia g&ecirc;nica, a qual precisa, urgentemente, ser elaborada tanto para evitar o uso inadequado das terapias quanto para controlar a produ&ccedil;&atilde;o e importa&ccedil;&atilde;o de insumos do exterior. No momento, resta &agrave;s autoridades sanit&aacute;rias aplicar normas consagradas no exterior para examinar eventuais pedidos de licen&ccedil;a ou fiscalizar ensaios cl&iacute;nicos e eventuais produtos de terapia g&ecirc;nica no pa&iacute;s.</font></p>     <p><font size="2" face="Verdana">Em todo o mundo, at&eacute; junho de 2010 haviam sido compilados cerca de 1.650 ensaios cl&iacute;nicos em terapia g&ecirc;nica na base de dados da revista <I>Journal of Gene Medicine</I> (<a href="http://www.wiley.co.uk/genmed/clinical/" target="_blank">http://www.wiley.co.uk/genmed/clinical/</a>). As <a href="#fig06">figuras 6&#45;11</a> ilustram os principais aspectos do estado atual da pesquisa cl&iacute;nica nessa &aacute;rea.</font></p>     <p><a name="fig06"></a></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p align="center"><img src="/img/revistas/ea/v24n70/a04fig06.jpg"></p>     <p>&nbsp;</p>     <p><a name="fig07"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig07.jpg"></p>     <p>&nbsp;</p>     <p><a name="fig08"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig08.jpg"></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><a name="fig09"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig09.jpg"></p>     <p>&nbsp;</p>     <p><a name="fig10"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig10.jpg"></p>     <p>&nbsp;</p>     <p><a name="fig11"></a></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p align="center"><img src="/img/revistas/ea/v24n70/a04fig11.jpg"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"> A distribui&ccedil;&atilde;o dos pa&iacute;ses&#45;sede de ensaios cl&iacute;nicos (<a href="#fig06">Figura 6</a>) corresponde, de modo geral, ao investimento feito na pesquisa fundamental em anos precedentes. Dentre os pa&iacute;ses componentes do grupo "outros", a base de dados do JGM inclui um ensaio sediado no M&eacute;xico e nenhum na Am&eacute;rica do Sul. De fato, dos 38 ensaios cl&iacute;nicos em andamento em pa&iacute;ses da Am&eacute;rica do Sul identificados ao final de 2009 na base de dados do Instituto Nacional de Sa&uacute;de dos EUA (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), 37 constituem extens&otilde;es de ensaios sediados em pa&iacute;ses do Hemisf&eacute;rio Norte e apenas um, iniciado em 2009, &eacute; de fato sediado na Am&eacute;rica do Sul, especificamente no Brasil (ver adiante). </font></p>     <p><font size="2" face="Verdana">A distribui&ccedil;&atilde;o em fases (<a href="#fig07">Figura 7</a>) reflete claramente o car&aacute;ter experimental da terapia g&ecirc;nica. Para compara&ccedil;&atilde;o, podem&#45;se citar dados do conjunto dos ensaios cl&iacute;nicos registrados na p&aacute;gina clinicaltrials.gov. Dentre esses ensaios, que incluem predominantemente f&aacute;rmacos e procedimentos cl&iacute;nicos e cir&uacute;rgicos convencionais, cerca de 45% s&atilde;o de fase II e pouco mais de 30% s&atilde;o de fase III. J&aacute;, como demonstrado no gr&aacute;fico da <a href="#fig07">Figura 7</a>, a maioria dos ensaios cl&iacute;nicos em terapia g&ecirc;nica ainda n&atilde;o passa da fase I e, at&eacute; o momento, apenas cerca de 4% progrediram at&eacute; as fases III e IV. Ainda assim, h&aacute; sinais de que a progress&atilde;o da terapia g&ecirc;nica experimental no sentido da pr&aacute;tica m&eacute;dica est&aacute; se acelerando (<a href="#fig08">Figura 8</a>).</font></p>     <p><font size="2" face="Verdana">A seguran&ccedil;a ainda &eacute; a principal barreira ao desenvolvimento da terapia g&ecirc;nica para a pr&aacute;tica m&eacute;dica. O principal entrave &eacute; o fato de que os vetores n&atilde;o virais mais seguros dispon&iacute;veis no momento s&atilde;o ainda pouco eficientes ou t&ecirc;m aplica&ccedil;&atilde;o muito limitada, como &eacute; o caso dos plasm&iacute;deos discutidos antes. A alta efici&ecirc;ncia de transdu&ccedil;&atilde;o de vetores virais torna estes &uacute;ltimos os mais promissores para aplica&ccedil;&atilde;o. Entretanto, alguns tipos, particularmente de vetores adenovirais e retrovirais, os mais utilizados at&eacute; hoje, produziram efeitos adversos, alguns graves e mesmo fatais, e contribu&iacute;ram fortemente para o bloqueio de muitos estudos na fase I. </font></p>     <p><font size="2" face="Verdana">Naturalmente, 150 anos de pesquisa fundamental em farmacologia oferecem uma base s&oacute;lida, sobre a qual quest&otilde;es de seguran&ccedil;a de medicamentos convencionais s&atilde;o frequentemente resolvidas nos laborat&oacute;rios de pesquisa b&aacute;sica ou em ensaios pr&eacute;&#45;cl&iacute;nicos consagrados e altamente preditivos. Ainda h&aacute; um longo caminho a percorrer at&eacute; que essa situa&ccedil;&atilde;o se torne rotina na pesquisa em terapia g&ecirc;nica.</font></p>     <p><font size="2" face="Verdana">A distribui&ccedil;&atilde;o dos ensaios cl&iacute;nicos por indica&ccedil;&atilde;o terap&ecirc;utica (<a href="#fig09">Figura 9</a>) corrobora um aspecto j&aacute; mencionado. Embora a terapia g&ecirc;nica tenha sido concebida originalmente com o objetivo de tratar doen&ccedil;as monog&ecirc;nicas, essas constituem hoje o alvo de menos de 10% dos ensaios cl&iacute;nicos. A predomin&acirc;ncia de c&acirc;ncer pode ser explicada, em parte, pela maior facilidade de aprova&ccedil;&atilde;o de ensaios cl&iacute;nicos baseados no uso compassionado de drogas ou terapias experimentais em pacientes terminais, mas tamb&eacute;m pelo grande avan&ccedil;o no desenho de v&iacute;rus oncol&iacute;ticos (que destroem c&eacute;lulas tumorais) e terapias com genes suicidas (ver adiante).</font></p>     <p><font size="2" face="Verdana">A variedade de genes utilizados nos ensaios cl&iacute;nicos (<a href="#fig10">Figura 10</a>) reflete o car&aacute;ter <I>ad hoc</I> da terapia g&ecirc;nica. &Eacute; prov&aacute;vel que o avan&ccedil;o dessa &aacute;rea de pesquisa m&eacute;dica seja fortemente influenciado pela tend&ecirc;ncia ao desenvolvimento de medicina personalizada, com base em avan&ccedil;os da gen&eacute;tica, da farmacogen&ocirc;mica e de outros campos de investiga&ccedil;&atilde;o moderna. Ainda assim, a preval&ecirc;ncia de ant&iacute;genos, citocinas, supressores de tumor e genes suicidas corresponde &agrave; predomin&acirc;ncia de c&acirc;ncer como indica&ccedil;&atilde;o terap&ecirc;utica mais frequente na pesquisa cl&iacute;nica nessa &aacute;rea.</font></p>     <p><font size="2" face="Verdana">O t&oacute;pico de vetores &eacute;, sem d&uacute;vida, o mais cr&iacute;tico para o avan&ccedil;o da terapia g&ecirc;nica no sentido da aplica&ccedil;&atilde;o &agrave; pr&aacute;tica m&eacute;dica. O gr&aacute;fico da <a href="#fig11">Figura 11</a> compila dados obtidos em duas d&eacute;cadas, ao longo das quais o progresso tecnol&oacute;gico na &aacute;rea de vetores foi extraordin&aacute;rio. Por exemplo, em contraposi&ccedil;&atilde;o ao tipo de vetor adenoviral que ensejou a morte de um paciente de um ensaio cl&iacute;nico em 1999 (ver adiante) e quase paralisou a pesquisa em terapia g&ecirc;nica, hoje est&atilde;o dispon&iacute;veis vetores adenovirais de terceira gera&ccedil;&atilde;o, radicalmente modificados no sentido de evitar efeitos adversos como o que vitimou aquele paciente. Cresce, contudo, a expectativa de utiliza&ccedil;&atilde;o de vetores virais intrinsecamente mais seguros, como os vetores derivados de v&iacute;rus adenoassociado.</font></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font size="3" face="Verdana"><b>Aplica&ccedil;&otilde;es da terapia g&ecirc;nica</b></font></p>     <p><font size="2" face="Verdana">Para ilustrar as aplica&ccedil;&otilde;es potenciais da terapia g&ecirc;nica, bem como a l&oacute;gica subjacente e a sequ&ecirc;ncia da pesquisa fundamental e pr&eacute;&#45;cl&iacute;nica que levou aos ensaios cl&iacute;nicos, foram selecionados alguns exemplos ilustrados a seguir. </font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><i><b>Doen&ccedil;as monog&ecirc;nicas</b></i></font></p>     <p><font size="2" face="Verdana"><B>Hemofilia</B>: Como cada tipo de hemofilia &eacute; uma doen&ccedil;a monog&ecirc;nica, o procedimento &eacute; o de introduzir o respectivo gene sadio (fator VIII ou fator IX, dependendo do tipo de hemofilia) em c&eacute;lulas do paciente, para que essas passem a produzir a prote&iacute;na necess&aacute;ria. A terapia deve n&atilde;o apenas fazer o organismo voltar a produzir a prote&iacute;na que falta, mas produzi&#45;la em quantidade suficiente para restabelecer a sa&uacute;de do paciente e por longo prazo, idealmente por toda a vida. </font></p>     <p><font size="2" face="Verdana">Ap&oacute;s extensos ensaios pr&eacute;&#45;cl&iacute;nicos em camundongos e c&atilde;es, que demonstraram recupera&ccedil;&atilde;o de longo prazo da atividade pr&oacute;&#45;coagulante mediada por fator IX introduzido por terapia g&ecirc;nica experimental, dois estudos de fase I/II foram realizados recentemente por um grupo da Universidade da Pensilv&acirc;nia, com aplica&ccedil;&atilde;o de um vetor derivado de v&iacute;rus adenoassociado (rAAV), contendo o gene codificante do fator IX em pacientes de hemofilia B (Manno et al., 2003, 2006; Hasbrouck &amp; High, 2008). N&atilde;o houve efeitos adversos s&eacute;rios em nenhum dos pacientes testados.</font></p>     <p><font size="2" face="Verdana">Os resultados indicam potencial efic&aacute;cia do tratamento, pois um paciente que recebeu uma dose elevada do rAAV&#45;F9 por infus&atilde;o hep&aacute;tica apresentou, entre duas e cinco semanas ap&oacute;s o tratamento, n&iacute;veis terap&ecirc;uticos de fator IX circulante acima de 10% da atividade normal, que &eacute; suficiente para sustentar a capacidade de coagula&ccedil;&atilde;o sangu&iacute;nea. Entretanto, o efeito terap&ecirc;utico foi transit&oacute;rio, desaparecendo seis semanas ap&oacute;s o tratamento, acompanhado de aumento tempor&aacute;rio e assintom&aacute;tico de n&iacute;veis de transaminases (<a href="#fig12">Figura 12</a>). Os resultados deste e de outro paciente no mesmo estudo indicaram que os efeitos terap&ecirc;uticos foram abolidos por degenera&ccedil;&atilde;o das c&eacute;lulas do f&iacute;gado nas quais foi introduzido o vetor, causada por uma resposta imune contra prote&iacute;nas do vetor viral (Mingozzi &amp; High, 2007). </font></p>     <p><a name="fig12"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig12.jpg"></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font size="2" face="Verdana">Esse exemplo &eacute; particularmente importante, porque em nenhum dos ensaios pr&eacute;&#45;cl&iacute;nicos realizados em animais antes da formula&ccedil;&atilde;o do estudo cl&iacute;nico, e nem mesmo em novos experimentos realizados ap&oacute;s a obten&ccedil;&atilde;o dos resultados do ensaio cl&iacute;nico citado, foram observadas nos animais de experimenta&ccedil;&atilde;o respostas imunit&aacute;rias que permitissem prever a resposta imune observada nos pacientes. O resultado demonstra a necessidade de cautela na transi&ccedil;&atilde;o de estudos pr&eacute;&#45;cl&iacute;nicos para ensaios cl&iacute;nicos, mesmo na aus&ecirc;ncia de efeitos adversos s&eacute;rios, e forneceu dados cruciais para o avan&ccedil;o da aplica&ccedil;&atilde;o cl&iacute;nica de terapia g&ecirc;nica. Novos estudos experimentais est&atilde;o em andamento, visando evitar essa resposta imunit&aacute;ria com o emprego de variantes do vetor e imunossupress&atilde;o transit&oacute;ria, que guiar&atilde;o novos ensaios cl&iacute;nicos (Hasbrouck &amp; High, 2008).</font></p>     <p><font size="2" face="Verdana"><B>Amaurose cong&ecirc;nita de Leber</B>: A partir do final de abril de 2008, foram tamb&eacute;m divulgados os primeiros resultados de ensaios cl&iacute;nicos de fase I/II para tratamento da amaurose cong&ecirc;nita de Leber (abreviada LCA, do ingl&ecirc;s <I>Leber's congenital amaurosis</I>). A LCA &eacute; uma doen&ccedil;a que provoca cegueira progressiva, iniciando&#45;se com perda importante de vis&atilde;o em beb&ecirc;s e progredindo ao longo do tempo para cegueira total. Inicialmente, os fotorreceptores, c&eacute;lulas retinianas sens&iacute;veis &agrave; luz e imprescind&iacute;veis para a vis&atilde;o, s&atilde;o inativados, mas permanecem vivos na retina (den Hollander et al., 2008). Com o passar dos anos, os fotorreceptores inativos, predominantemente os bastonetes que funcionam em baixos n&iacute;veis de luminosidade, degeneram e desaparecem (Spuy et al., 2005).</font></p>     <p><font size="2" face="Verdana">H&aacute; v&aacute;rias formas de LCA, algumas de causa gen&eacute;tica j&aacute; bem conhecida, como a defici&ecirc;ncia da RPE65, uma enzima necess&aacute;ria para produzir o derivado de vitamina A essencial para o funcionamento dos fotorreceptores (Poehner et al., 2000; Bereta et al., 2008). Os fotorreceptores desses pacientes perdem paulatinamente a fun&ccedil;&atilde;o, mas sua degenera&ccedil;&atilde;o s&oacute; costuma acontecer por volta dos 30 anos de idade (Hollander et al., 2008). Esse curso da doen&ccedil;a oferece uma janela terap&ecirc;utica para inser&ccedil;&atilde;o de c&oacute;pias normais do gene que codifica a RPE65 na retina de adultos jovens portadores desse tipo de LCA (<a href="#fig13">Figura 13</a>). Os testes s&atilde;o ainda preliminares, e, em princ&iacute;pio, somente tr&ecirc;s pacientes foram testados em cada um de tr&ecirc;s ensaios cl&iacute;nicos de fase I realizados na Inglaterra e nos Estados Unidos (Bainbridge et al., 2008; Maguire et al., 2008; Cideciyan et al., 2008; Hauswirth et al., 2008).</font></p>     <p><a name="fig13"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig13.jpg"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana">Os primeiros resultados mostraram que a introdu&ccedil;&atilde;o dos vetores derivados de adenov&iacute;rus&#45;associado contendo o gene normal na retina dos pacientes n&atilde;o provocou efeitos adversos importantes. Foi observada melhora em exames oftalmol&oacute;gicos e no desempenho visual de alguns doentes, que recuperaram parcialmente a sensibilidade &agrave; luz (Hauswirth et al., 2008) e a capacidade de se orientar em ambientes de baixa luminosidade, o que n&atilde;o conseguiam fazer antes da introdu&ccedil;&atilde;o do gene sadio (Bainbridge et al., 2008).</font></p>     <p><font size="2" face="Verdana">Os resultados at&eacute; agora, entretanto, foram obtidos em poucos pacientes, ainda n&atilde;o foram observados sinais de melhora em certos testes oftalmol&oacute;gicos cruciais (Hauswirth et al., 2008) e a defici&ecirc;ncia de RPE65 &eacute; respons&aacute;vel por apenas 6% dos casos de LCA (Hollander et al., 2008). Ou seja, a terapia que est&aacute; em teste no momento, se for bem&#45;sucedida, s&oacute; poder&aacute; ser aplicada a uma fra&ccedil;&atilde;o pequena dos doentes. Tratamentos para os demais grupos de pacientes ter&atilde;o de ser desenvolvidos caso a caso. Ainda assim, trata&#45;se de um avan&ccedil;o importante no desenvolvimento de novas terapias para doen&ccedil;as que levam &agrave; cegueira, e j&aacute; est&aacute; em andamento um ensaio cl&iacute;nico fase II para confirmar (ou n&atilde;o), de forma sistem&aacute;tica, a poss&iacute;vel efic&aacute;cia do tratamento.</font></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font size="3" face="Verdana"><i><b>C&acirc;ncer</b></i></font></p>     <p><font size="2" face="Verdana">A maioria dos ensaios cl&iacute;nicos de terapia g&ecirc;nica tem sido feita em pacientes de c&acirc;ncer (<a href="#fig09">Figura 9</a>), em geral em est&aacute;gios avan&ccedil;ados. O efeito desej&aacute;vel de qualquer tratamento para o c&acirc;ncer &eacute; o de provocar a morte seletiva das c&eacute;lulas tumorais (Evan &amp; Littlewood, 1998; Green &amp; Evan, 2002). C&eacute;lulas cancerosas geralmente multiplicam&#45;se com rapidez, o que explica o crescimento dos tumores. Muitos f&aacute;rmacos s&atilde;o usados no tratamento do c&acirc;ncer justamente porque atacam seletivamente c&eacute;lulas que se multiplicam com rapidez e, portanto, matam c&eacute;lulas tumorais (Wang et al., 2008; Prochownik, 2008; Vazquez et al., 2008). </font></p>     <p><font size="2" face="Verdana">A necessidade fisiol&oacute;gica de renova&ccedil;&atilde;o cont&iacute;nua das c&eacute;lulas do sangue, a partir da prolifera&ccedil;&atilde;o de precursores na medula &oacute;ssea, implica, entretanto, efeitos adversos graves da quimioterapia. Esses efeitos s&atilde;o dif&iacute;ceis de evitar, pois, entre outros fatores, os medicamentos s&atilde;o injetados na circula&ccedil;&atilde;o. Para tratamento de c&acirc;ncer, &eacute; desej&aacute;vel atingir, de alguma forma, apenas as c&eacute;lulas tumorais. No caso de tumores s&oacute;lidos, como tumores originados no sistema nervoso central, isso &eacute; poss&iacute;vel mediante terapia g&ecirc;nica localizada (Rainov &amp; Ren, 2003), e v&aacute;rias estrat&eacute;gias v&ecirc;m sendo desenvolvidas nesse sentido (<a href="#tab02">Tabela 2</a>).</font></p>     <p><a name="tab02"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04tab02.jpg"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana">O procedimento apelidado de "t&eacute;cnica de genes suicidas" consiste em introduzir nas c&eacute;lulas tumorais um gene que n&atilde;o existe no genoma humano e codifica a enzima timidina cinase, proveniente do genoma do herpesv&iacute;rus. A presen&ccedil;a dessa enzima em uma c&eacute;lula humana mata a c&eacute;lula na presen&ccedil;a de uma droga chamada ganciclovir, pois a timidina cinase transforma o ganciclovir em uma toxina. A toxina, por sua vez, s&oacute; afeta c&eacute;lulas que se multiplicam (<a href="#fig14">Figura 14</a>). </font></p>     <p><a name="fig14"></a></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig14.jpg"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana">Embora a efic&aacute;cia da tecnologia de gene suicida para tratamento de tumores seja ainda controversa, alguns estudos obtiveram resultados animadores. Dentre eles, um ensaio cl&iacute;nico de fase I/II realizado na Finl&acirc;ndia, no qual a ressec&ccedil;&atilde;o de tumores extremamente agressivos do sistema nervoso central, denominados glioblastomas, foi seguida por inje&ccedil;&atilde;o, no leito cir&uacute;rgico, de um vetor adenoviral contendo o gene da timidina cinase de herpesv&iacute;rus. O procedimento prosseguiu com inje&ccedil;&otilde;es endovenosas di&aacute;rias de ganciclovir por 14 dias. A terapia g&ecirc;nica resultou em aumento significativo da sobrevida (<a href="#fig15">Figura 15</a>) do grupo de 17 pacientes tratados por terapia g&ecirc;nica, quando comparado a um grupo de 19 pacientes tratados com terapia convencional, ou quando comparado a uma popula&ccedil;&atilde;o controle de 36 pacientes previamente tratados por m&eacute;todos convencionais na mesma unidade de neurocirurgia, nos dois anos anteriores ao ensaio (Immonen et al., 2004). O vetor utilizado nesse estudo est&aacute; sendo desenvolvido pela empresa Ark Therapeutics que, recentemente, relatou resultados positivos significativos de um estudo multic&ecirc;ntrico de fase III com 250 pacientes e, em fevereiro de 2009, obteve na Fran&ccedil;a a primeira autoriza&ccedil;&atilde;o para uso compassionado do produto, denominado Cerepro&#174;.</font></p>     <p><a name="fig15"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig15.jpg"></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><i><b>Doen&ccedil;a de Parkinson</b></i></font></p>     <p><font size="2" face="Verdana">As doen&ccedil;as neurodegenerativas s&atilde;o uma das classes mais problem&aacute;ticas para a medicina contempor&acirc;nea. Apesar dos avan&ccedil;os ocorridos desde os anos 1990, per&iacute;odo denominado "d&eacute;cada do c&eacute;rebro" (Goldstein, 1994), e do extenso conjunto de conhecimentos acumulados sobre diversos aspectos da patog&ecirc;nese, gen&eacute;tica, curso cl&iacute;nico, complica&ccedil;&otilde;es e resposta aos diversos tratamentos testados ao longo de anos de investiga&ccedil;&atilde;o, h&aacute; uma consp&iacute;cua car&ecirc;ncia de op&ccedil;&otilde;es terap&ecirc;uticas, particularmente nos est&aacute;gios mais avan&ccedil;ados destas doen&ccedil;as (Radunovic et al., 2007; Cacabelos, 2007; Han &amp; McDonald, 2008; Jalbert et al., 2008; Gauthier &amp; Poirier, 2008; Olanow et al., 2008). </font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">Por sua vez, algumas neurodegenera&ccedil;&otilde;es s&atilde;o ilustrativas do potencial de desenvolvimento de terapia g&ecirc;nica para doen&ccedil;as multifatoriais e de alta complexidade. A doen&ccedil;a de Parkinson (DP) &eacute; um exemplo dessa categoria.</font></p>     <p><font size="2" face="Verdana">A DP &eacute; caracterizada por perda progressiva de neur&ocirc;nios na parte compacta da subst&acirc;ncia negra do mesenc&eacute;falo e altera&ccedil;&otilde;es funcionais em outros n&uacute;cleos do tronco cerebral (<a href="#fig16">Figura 16</a>), acompanhada da forma&ccedil;&atilde;o de inclus&otilde;es intracelulares denominadas corpos de Lewy. Isso resulta em deple&ccedil;&atilde;o de dopamina, o neurotransmissor utilizado pelos neur&ocirc;nios que degeneram, no alvo dos prolongamentos dos neur&ocirc;nios da subst&acirc;ncia negra, que se chama corpo estriado. Com a evolu&ccedil;&atilde;o da doen&ccedil;a, encontra&#45;se adicionalmente o envolvimento de outros sistemas de neurotransmissores. Os dist&uacute;rbios motores t&iacute;picos da doen&ccedil;a, como tremor de repouso, lentid&atilde;o dos movimentos e rigidez muscular, s&atilde;o frequentemente acompanhados por instabilidade postural, disfun&ccedil;&atilde;o visceral e dist&uacute;rbios cognitivos (Guttman et al., 2003). Os mecanismos que levam &agrave; morte dos neur&ocirc;nios da subst&acirc;ncia negra s&atilde;o ainda controversos (Dawson &amp; Dawson, 2003; Dauer &amp; Przedborski, 2003).</font></p>     <p><a name="fig16"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig16.jpg"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana">O tratamento farmacol&oacute;gico com L&#45;Dopa, um medicamento precursor da s&iacute;ntese de dopamina, &eacute; eficaz em curto ou m&eacute;dio prazo, mas tende a se tornar in&oacute;cuo com a perda progressiva dos neur&ocirc;nios, al&eacute;m de eventualmente provocar dist&uacute;rbios motores adicionais. A progress&atilde;o da doen&ccedil;a exige doses mais elevadas e combina&ccedil;&otilde;es de medicamentos, que nem sempre se mostram eficazes (Poewe, 2009). Terapias celulares destinadas a repor neur&ocirc;nios dopamin&eacute;rgicos na subst&acirc;ncia negra poder&atilde;o, eventualmente, beneficiar pacientes de DP, mas, at&eacute; o momento, os ensaios cl&iacute;nicos efetuados com transplantes de tecido nervoso fetal tiveram efeitos discretos, bem como sugeriram a possibilidade de transmiss&atilde;o da doen&ccedil;a para o tecido transplantado (Thajeb et al., 1997; Li et al., 2008; Kordower et al., 2008; Mendez et al., 2008; Braak &amp; Del Tredici, 2008).</font></p>     <p><font size="2" face="Verdana">Estrat&eacute;gias de terapia g&ecirc;nica para tratamento da doen&ccedil;a de Parkinson incluem a indu&ccedil;&atilde;o da produ&ccedil;&atilde;o local de dopamina no estriado, a oferta de fatores neurotr&oacute;ficos para reduzir a perda progressiva de neur&ocirc;nios dopamin&eacute;rgicos ou, ainda, a compensa&ccedil;&atilde;o do desequil&iacute;brio funcional na rede de comunica&ccedil;&atilde;o celular dos n&uacute;cleos da base (Chen et al., 2005).</font></p>     <p><font size="2" face="Verdana">A produ&ccedil;&atilde;o de dopamina depende essencialmente da atividade de tr&ecirc;s enzimas. As t&eacute;cnicas destinadas a produzir dopamina no corpo estriado depletado envolvem, em geral, a indu&ccedil;&atilde;o de uma ou mais destas enzimas por meio de vetores virais (Kang et al., 2001). Os modelos experimentais pr&eacute;&#45;cl&iacute;nicos consistem em les&otilde;es qu&iacute;micas da subst&acirc;ncia negra em ratos ou em primatas. Foram testados v&aacute;rios tipos de vetores virais (Chen et al., 2005 para revis&atilde;o). Com base nos resultados dos estudos pr&eacute;&#45;cl&iacute;nicos, foi iniciado um ensaio cl&iacute;nico fase I destinado a testar a seguran&ccedil;a e, secundariamente, efeitos ben&eacute;ficos de terapia g&ecirc;nica por express&atilde;o de uma das enzimas produtoras (a AADC), veiculada por vetor adenoviral&#45;associado injetado no corpo estriado de pacientes que sofrem da DP, em m&eacute;dia, h&aacute; 14 anos (<a href="http://clinicaltrials.gov/show/NCT00229736" target="_blank">http://clinicaltrials.gov/show/NCT00229736</a>). Os resultados (Christine et al., 2009) demonstraram melhora do quadro cl&iacute;nico sem efeitos adversos da terapia g&ecirc;nica <I>per se</I>, embora tenham sido detectados riscos no procedimento operat&oacute;rio.</font></p>     <p><font size="2" face="Verdana">Por sua vez, estrat&eacute;gias de neuroprote&ccedil;&atilde;o, destinadas a reduzir ou impedir a perda neuronal a longo prazo, t&ecirc;m sido formuladas com base em diversos fatores de crescimento que t&ecirc;m efeito protetor sobre neur&ocirc;nios da subst&acirc;ncia negra. Dentre os experimentos feitos em animais, um estudo testou os efeitos da inje&ccedil;&atilde;o, no corpo estriado, de um vetor viral expressando uma constru&ccedil;&atilde;o do gene de neurturina, com resultados positivos (Fjord&#45;Larsen et al., 2005). Assim, um ensaio cl&iacute;nico fase I foi iniciado em meados de 2005, visando examinar a seguran&ccedil;a de um vetor viral adenoassociado expressando o gene de neurturina injetado no corpo estriado (<a href="http://clinicaltrials.gov/show/NCT00252850" target="_blank">http://clinicaltrials.gov/show/NCT00252850</a>). N&atilde;o houve efeitos adversos graves em 12 pacientes tratados com duas doses distintas do vetor, e foram detectados efeitos ben&eacute;ficos em alguns par&acirc;metros motores (Marks et al., 2008). Um estudo multic&ecirc;ntrico de fase II encontra&#45;se, agora, em andamento.</font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">A terceira estrat&eacute;gia de terapia g&ecirc;nica para DP &eacute; baseada no desequil&iacute;brio funcional entre vias excitadoras e inibidoras nos n&uacute;cleos da base, consequente &agrave; perda da atividade da subst&acirc;ncia negra (<a href="#fig16">Figura 16</a>). Nessas condi&ccedil;&otilde;e, ocorre desinibi&ccedil;&atilde;o da atividade de um n&uacute;cleo chamado n&uacute;cleo subtal&acirc;mico (STN), &agrave; qual se atribui importante papel nos principais sinais da DP (Nakano, 2000; Chen et al., 2005). V&aacute;rios estudos demonstraram que remo&ccedil;&atilde;o cir&uacute;rgica do STN ou estimula&ccedil;&atilde;o el&eacute;trica de alta frequ&ecirc;ncia tem efeitos ben&eacute;ficos sobre alguns desses sinais, justificando o emprego da chamada estimula&ccedil;&atilde;o cerebral profunda no tratamento de casos avan&ccedil;ados de DP (Diamond &amp; Jankovic, 2005). O conhecimento das propriedades funcionais de circuitos neurais envolvidos na doen&ccedil;a levou a um exemplo not&aacute;vel de interven&ccedil;&atilde;o gen&eacute;tica destinada a modular a fisiologia do sistema nervoso, independentemente da causa da doen&ccedil;a que, ainda hoje, continua controversa.</font></p>     <p><font size="2" face="Verdana">Foi desenvolvido um ensaio de terapia g&ecirc;nica que consiste na indu&ccedil;&atilde;o de express&atilde;o de enzimas que produzem um neurotransmissor inibidor, visando contrapor&#45;se ao excesso de atividade neural no STN. A express&atilde;o dessas enzimas no STN produziu efeitos funcionais ben&eacute;ficos em modelo de DP em ratos (Luo et al., 2002). Com base nesses resultados, foi conduzido, no per&iacute;odo 2003&#45;2005, um ensaio cl&iacute;nico de fase I de terapia g&ecirc;nica empregando um vetor de v&iacute;rus adenoassociado recombinante, contendo o gene que codifica uma dessas enzimas, injetado no STN (<a href="http://www.clinicaltrials.gov/ct/show/NCT00195143" target="_blank">http://www.clinicaltrials.gov/ct/show/NCT00195143</a>). Resultados de 11 pacientes acompanhados por at&eacute; 12 meses indicaram melhora significativa de desempenho motor, acompanhada de redu&ccedil;&atilde;o de atividade metab&oacute;lica em alvos de proje&ccedil;&atilde;o do STN, compat&iacute;vel com os resultados dos estudos pr&eacute;&#45;cl&iacute;nicos. Foi tamb&eacute;m divulgada melhora significativa em escala de atividades cotidianas, que reflete a opini&atilde;o dos pacientes sobre seu desempenho em tarefas do dia a dia. N&atilde;o foram relatados efeitos adversos que deponham contra a seguran&ccedil;a do procedimento (Kaplitt et al., 2007).</font></p>     <p><font size="2" face="Verdana">Os resultados dos ensaios cl&iacute;nicos descritos s&atilde;o, ainda, muito preliminares, foram obtidos em n&uacute;meros reduzidos de pacientes e necessitam de confirma&ccedil;&atilde;o em ensaios mais amplos, com controles mais rigorosos para efeito placebo e outras vari&aacute;veis. Portanto, &eacute; ainda cedo para concluir sobre a viabilidade e, particularmente, a efic&aacute;cia de terapia g&ecirc;nica para doen&ccedil;as neurodegenerativas. Entretanto, esses estudos somam&#45;se a outros ensaios cl&iacute;nicos que sugerem que a terapia g&ecirc;nica poder&aacute; se transformar em alternativa efetiva de tratamento para doen&ccedil;as hoje incur&aacute;veis.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>O balan&ccedil;o risco&#45;benef&iacute;cio da terapia g&ecirc;nica</b></font></p>     <p><font size="2" face="Verdana">Dentre as centenas de ensaios cl&iacute;nicos de terapia g&ecirc;nica j&aacute; encerrados, a maioria destinou&#45;se a testar a seguran&ccedil;a do procedimento. Em certos casos, a identifica&ccedil;&atilde;o precoce de efeitos adversos durante o estudo foi suficiente para encerrar imediatamente o teste, evitando risco de agravamento. Mas, em muitos casos, o procedimento empregado foi considerado seguro, quando muito com efeitos adversos ocasionais, discretos e toler&aacute;veis. </font></p>     <p><font size="2" face="Verdana">Dor ou inflama&ccedil;&atilde;o leves no local da inje&ccedil;&atilde;o, febre baixa transit&oacute;ria, dor de cabe&ccedil;a passageira, sintomas semelhantes &agrave; gripe e outros efeitos suaves s&atilde;o, em geral, toler&aacute;veis em vista do potencial de tratamento de uma doen&ccedil;a incur&aacute;vel. Esses s&atilde;o a maior parte dos incidentes que se costuma encontrar nos ensaios cl&iacute;nicos de fase I em terapia g&ecirc;nica, especialmente ap&oacute;s a realiza&ccedil;&atilde;o de extensos testes pr&eacute;&#45;cl&iacute;nicos em animais, exigidos pelas ag&ecirc;ncias reguladoras para autoriza&ccedil;&atilde;o de ensaios cl&iacute;nicos (acesso a ag&ecirc;ncias reguladoras nos Estados Unidos e Europa e regulamenta&ccedil;&atilde;o nessa &aacute;rea pode ser obtido, por exemplo, pelo <I>link</I> <a href="http://www.genetherapynet.com/legislation.html" target="_blank">http://www.genetherapynet.com/legislation.html</a>). </font></p>     <p><font size="2" face="Verdana">Rea&ccedil;&otilde;es imunit&aacute;rias, entretanto, n&atilde;o apenas podem provocar efeitos adversos, mas, mesmo que n&atilde;o o fa&ccedil;am, podem destruir os vetores ou as c&eacute;lulas infectadas por vetores virais, em que pese o uso de t&eacute;cnicas sofisticadas de DNA recombinante em sua fabrica&ccedil;&atilde;o. Esse foi o caso do ensaio para hemofilia do tipo B, j&aacute; descrito (Mingozzi &amp; High, 2007), mas que n&atilde;o trouxe consequ&ecirc;ncias significativas aos pacientes. Em outros casos, no entanto, os efeitos adversos podem ser muito severos ou, em raros casos, fatais.</font></p>     <p><font size="2" face="Verdana">Em 1999, um paciente morreu logo ap&oacute;s a inje&ccedil;&atilde;o de um vetor viral durante um ensaio cl&iacute;nico de terapia g&ecirc;nica, vitimado por uma s&iacute;ndrome de resposta inflamat&oacute;ria sist&ecirc;mica causada pelo vetor adenoviral de primeira gera&ccedil;&atilde;o (Raper et al., 1998, 2003). Em ensaios cl&iacute;nicos mais recentes, realizados na Fran&ccedil;a e Inglaterra (Hacein&#45;Bey&#45;Abina et al., 2002; Gaspar et al., 2004), de um total de 20 crian&ccedil;as abaixo de um ano de idade submetidas a terapia g&ecirc;nica para s&iacute;ndrome de imunodefici&ecirc;ncia combinada severa ligada ao cromossomo X (SCID&#45;XL) (Buckley, 2004), cinco desenvolveram leucemias (Hacein&#45;Bey&#45;Abina et al., 2003; Howe et al., 2008). Dessas, uma foi a &oacute;bito e quatro apresentaram remiss&atilde;o completa da leucemia ap&oacute;s quimioterapia. Exames feitos ap&oacute;s o aparecimento das leucemias revelaram que os vetores retrovirais utilizados em ambos os ensaios produziram mutag&ecirc;nese insercional, ou seja, muta&ccedil;&otilde;es produzidas pela intromiss&atilde;o do vetor no DNA, rompendo a continuidade da sequ&ecirc;ncia gen&eacute;tica (Cavazzana&#45;Calvo &amp; Fischer, 2007; Howe et al., 2008). </font></p>     <p><font size="2" face="Verdana">Os casos citados constituem os mais graves exemplos efetivamente caracterizados como efeitos adversos diretos da terapia g&ecirc;nica. Ambos t&ecirc;m origem em caracter&iacute;sticas dos vetores virais utilizados. Por&eacute;m, em ambos os casos, a pesquisa fundamental, aliada &agrave; observa&ccedil;&atilde;o criteriosa dos eventos associados ao tratamento e ao curso cl&iacute;nico dos efeitos colaterais, contribuiu para avan&ccedil;os no desenho e produ&ccedil;&atilde;o de novos vetores, destinados a evitar tais efeitos adversos. </font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">No caso de vetores adenovirais, em contraposi&ccedil;&atilde;o &agrave; primeira gera&ccedil;&atilde;o de vetores empregada no ensaio cl&iacute;nico que resultou no caso fatal de 1999, j&aacute; est&atilde;o dispon&iacute;veis vetores adenovirais de terceira gera&ccedil;&atilde;o, constru&iacute;dos com dele&ccedil;&atilde;o completa de genes virais e capazes de transdu&ccedil;&atilde;o g&ecirc;nica muito mais segura em seres humanos (R&auml;ty et al., 2008; Dormond et al., 2009). Por sua vez, &eacute; crescente a expectativa de evitar mutag&ecirc;nese insercional, como a observada nos ensaios para SCID&#45;XL, por meio do desenho de vetores retrovirais ou lentivirais autoinativantes ou dotados de isoladores de cromatina, duas das mais promissoras t&eacute;cnicas em desenvolvimento atualmente para essa classe de vetores (Yi et al., 2005; R&auml;ty et al., 2008).</font></p>     <p><font size="2" face="Verdana">A terapia g&ecirc;nica para SCID&#45;XL, por sua vez, foi curativa em 19 das 20 crian&ccedil;as tratadas, que apresentaram melhora significativa do seu sistema imune menos de tr&ecirc;s meses ap&oacute;s o tratamento, bem como recupera&ccedil;&atilde;o persistente de sua resist&ecirc;ncia a infec&ccedil;&otilde;es (<a href="#tab03">Tabela 3</a>; Fisher &amp; Cavazzana&#45;Calvo, 2008; Aiuti &amp; Roncarolo, 2009). Por seu turno, o tratamento em adolescentes n&atilde;o foi eficaz, sugerindo uma janela terap&ecirc;utica limitada para interven&ccedil;&atilde;o nessa doen&ccedil;a. Adicionam&#45;se aos casos bem&#45;sucedidos 30 pacientes tratados da SCID&#45;ADA, a forma de imunodefici&ecirc;ncia que corresponde &agrave; primeira paciente tratada por terapia g&ecirc;nica em 1989 (<a href="#tab04">Tabela 4</a>; Aiuti &amp; Roncarolo, 2009).</font></p>     <p><a name="tab03"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04tab03.jpg"></p>     <p>&nbsp;</p>     <p><a name="tab04"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04tab04.jpg"></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">As ag&ecirc;ncias reguladoras envolvidas na autoriza&ccedil;&atilde;o e no controle de ensaios cl&iacute;nicos em terapia g&ecirc;nica agiram rapidamente em ambos os casos de efeitos adversos aqui relatados. Em 1999, o ensaio que resultou na morte do paciente foi suspenso definitivamente, apesar da aus&ecirc;ncia de efeitos adversos graves nos outros 17 pacientes tratados no mesmo estudo. No caso dos ensaios para SCID&#45;XL, os procedimentos terap&ecirc;uticos j&aacute; estavam encerrados, mas as autoriza&ccedil;&otilde;es para outros ensaios semelhantes foram suspensas at&eacute; a avalia&ccedil;&atilde;o criteriosa dos dados e, posteriormente, voltaram a ser concedidas. Em que pese o reconhecimento de que o procedimento de terapia g&ecirc;nica foi respons&aacute;vel pelos efeitos adversos, os comit&ecirc;s reguladores conclu&iacute;ram que nenhum desses eventos, assim como outros efeitos adversos relatados ocasionalmente, justifica a aboli&ccedil;&atilde;o de ensaios cl&iacute;nicos em terapia g&ecirc;nica. Na verdade, a an&aacute;lise dos efeitos adversos tem contribu&iacute;do para orientar o desenvolvimento biotecnol&oacute;gico na &aacute;rea e, ao mesmo tempo, aperfei&ccedil;oar a regulamenta&ccedil;&atilde;o e os crit&eacute;rios para autoriza&ccedil;&atilde;o de ensaios cl&iacute;nicos.</font></p>     <p><font size="2" face="Verdana">O balan&ccedil;o de efeitos adversos e benef&iacute;cios em ensaios cl&iacute;nicos de terapia g&ecirc;nica indica que o curso do desenvolvimento dessa, assim como de outras terapias avan&ccedil;adas, tais como os tratamentos com c&eacute;lulas&#45;tronco, ser&aacute; tanto mais seguro quanto mais bem fundamentado pela pesquisa b&aacute;sica e sujeito a regulamenta&ccedil;&atilde;o adequada para restringir a autoriza&ccedil;&atilde;o de ensaios cl&iacute;nicos &agrave; condi&ccedil;&atilde;o de m&aacute;xima seguran&ccedil;a poss&iacute;vel na &eacute;poca dos ensaios, por&eacute;m sem tolher o avan&ccedil;o da pesquisa m&eacute;dica.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Terapia g&ecirc;nica e biotecnologia</b></font></p>     <p><font size="2" face="Verdana">Empres&aacute;rios da &aacute;rea de biotecnologia enxergam no sequenciamento do genoma humano oportunidades comerciais crescentes. O interesse reside, naturalmente, no fato de que a descoberta dos genes e, especialmente de muta&ccedil;&otilde;es respons&aacute;veis, no todo ou em parte, por uma doen&ccedil;a, pode levar ao desenvolvimento de testes diagn&oacute;sticos ou medicamentos comercializ&aacute;veis.</font></p>     <p><font size="2" face="Verdana">Entre outras a&ccedil;&otilde;es, empresas come&ccedil;aram a investir no patenteamento de genes ou mesmo de sequ&ecirc;ncias de fragmentos de DNA que ainda n&atilde;o tinham sequer sido associadas a genes propriamente ditos. Mais de tr&ecirc;s milh&otilde;es de patentes relacionadas ao genoma foram solicitadas at&eacute; hoje nos Estados Unidos. A legisla&ccedil;&atilde;o norte&#45;americana em geral permite o patenteamento de genes, desde que isolados (e n&atilde;o apenas descritos como sequ&ecirc;ncias de nucleot&iacute;deos) e acompanhados de evid&ecirc;ncia de utilidade, por exemplo, para desenvolvimento de testes diagn&oacute;sticos. Entretanto, o patenteamento de genes &eacute; controverso. Por exemplo, as normas internas para avalia&ccedil;&atilde;o da utilidade de descobertas relativas a genes, em vigor desde 2001 pelo Escrit&oacute;rio de Patentes dos Estados Unidos (Uspto), foram e ainda s&atilde;o objeto de severas cr&iacute;ticas, das quais o Uspto se defende com base nas leis de patentes vigentes nos Estados Unidos. J&aacute; o Instituto Nacional da Propriedade Industrial (Inpi), &oacute;rg&atilde;o brasileiro que concede patentes com validade nacional, informa em sua p&aacute;gina que o patenteamento de genes naturais n&atilde;o &eacute; permitido no Brasil.</font></p>     <p><font size="2" face="Verdana">Fora do &acirc;mbito da controv&eacute;rsia sobre patenteamento de genes, os vetores para terapia g&ecirc;nica, virais ou n&atilde;o virais, contendo genes terap&ecirc;uticos, bem como suas aplica&ccedil;&otilde;es espec&iacute;ficas, s&atilde;o produtos de desenvolvimento tecnol&oacute;gico e, como tal, constituem objeto leg&iacute;timo de patenteamento e eventual comercializa&ccedil;&atilde;o (Bobrow &amp; Thomas, 2002). Centenas de patentes desse tipo t&ecirc;m sido solicitadas ao Uspto e a seus similares europeus e asi&aacute;ticos. Dezenas de empresas v&ecirc;m investindo em terapia g&ecirc;nica, a partir de tecnologias patenteadas de produ&ccedil;&atilde;o de vetores ou como parceiras de institui&ccedil;&otilde;es de pesquisa (<a href="#tab05">Tabela 5</a>).</font></p>     <p><a name="tab05"></a></p>     <p>&nbsp;</p>     <p align="center">   <img src="/img/revistas/ea/v24n70/a04tab05.jpg" border="0" usemap="#Map">   <map name="Map">       <area shape="poly" coords="573,555,571,551,573,537,526,537,528,554,5,556,3,571,270,570" href="http://www.ispex.ca/companies/genetherapy.html" target="_blank">     <area shape="poly" coords="252,564" href="#">   </map> </p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><font size="2" face="Verdana">Em todo o mundo, as primeiras etapas de desenvolvimento de tecnologias para terapia g&ecirc;nica e muitos testes pr&eacute;&#45;cl&iacute;nicos est&atilde;o ao alcance de grupos de pesquisa, institutos e universidades p&uacute;blicas, bem como entidades privadas financiadas com recursos p&uacute;blicos. Entretanto, a transfer&ecirc;ncia da pesquisa de laborat&oacute;rio para o ensaio cl&iacute;nico geralmente demanda recursos que est&atilde;o muito al&eacute;m da capacidade de financiamento p&uacute;blico. Companhias de biotecnologia investem na realiza&ccedil;&atilde;o desses ensaios em raz&atilde;o da exist&ecirc;ncia de patentes que possam ser, eventualmente, exploradas comercialmente, assim como em todas as demais &aacute;reas de tecnologia. At&eacute; o momento, apenas um produto especificamente classificado como terapia g&ecirc;nica foi comercializado, mas outros quatro produtos encontram&#45;se em fase adiantada no caminho da comercializa&ccedil;&atilde;o (<a href="#tab06">Tabela 6</a>).</font></p>     <p><a name="tab06"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04tab06.jpg"></p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana">O interesse do setor industrial na terapia g&ecirc;nica pode ser ilustrado por dados provenientes de organiza&ccedil;&otilde;es especializadas em prospec&ccedil;&atilde;o tecnol&oacute;gica. A an&aacute;lise da evolu&ccedil;&atilde;o do n&uacute;mero de produtos destinados &agrave; terapia g&ecirc;nica, em fase de desenvolvimento por parte de empresas, revela um aspecto importante. Enquanto a produ&ccedil;&atilde;o cient&iacute;fica na &aacute;rea cresce continuamente (<a href="#fig05">Figura 5</a>), a curva de crescimento do investimento industrial apresentou uma clara redu&ccedil;&atilde;o entre 2003 e 2007 (<a href="#fig17">Figura 17</a>), provavelmente influenciada pelos efeitos adversos dos ensaios de terapia g&ecirc;nica para SCID&#45;XL, que foram amplamente divulgados e, naturalmente, devem ter despertado preocupa&ccedil;&atilde;o por parte dos investidores. Ainda assim, o n&uacute;mero de produtos industriais nas fases II e III continuou crescendo no per&iacute;odo (<a href="#fig18">Figura 18</a>) e a recupera&ccedil;&atilde;o do crescimento do setor &eacute; previs&iacute;vel. No meio empresarial, h&aacute; uma expectativa crescente de sucessos a um prazo compat&iacute;vel com os investimentos tanto na pesquisa acad&ecirc;mica quanto no setor privado (Phacilitate, 2009).  Um estudo estrat&eacute;gico de 2008 previu um mercado mundial de cerca de US$ 500 milh&otilde;es de d&oacute;lares em 2015 para produtos de terapia g&ecirc;nica (Global Industry Analysts &#150; Gene Therapy: a global strategic business report, 2008). </font></p>     <p><a name="fig17"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig17.jpg" border="0" usemap="#Map2"> <map name="Map2"> <area shape="poly" coords="526,512,526,524" href="#"> <area shape="poly" coords="576,513" href="#"><area shape="poly" coords="524,524,525,508,578,510,576,527,76,531,79,543,533,544,536,532" href="#"> <area shape="poly" coords="390,541,387,533" href="#"> <area shape="poly" coords="324,538" href="#"><area shape="poly" coords="532,513" href="http://www.pharmaprojects.com/therapy_analysis/genether_early_0409.htm" target="_blank"> </map></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p><a name="fig18" id="fig18"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04fig18.jpg" border="0" usemap="#Map3"> <map name="Map3"> <area shape="poly" coords="387,505,386,487" href="#"> <area shape="poly" coords="389,503,385,488,571,485,570,506,76,511,80,523,407,525,409,511" href="http://www.pharmaprojects.com/therapy_analysis/genether_current_0409.htm" target="_blank"> </map></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Terapia g&ecirc;nica no Brasil</b></font></p>     <p><font size="2" face="Verdana">Apesar da hist&oacute;ria e do reconhecimento internacional da gen&eacute;tica brasileira, ainda h&aacute; poucos grupos de pesquisa dedicados a estudos sobre terapia g&ecirc;nica, incluindo vacinas de DNA. At&eacute; recentemente havia pouco investimento p&uacute;blico nessa &aacute;rea de investiga&ccedil;&atilde;o e nenhum interesse por parte do setor privado. O quadro, no entanto, est&aacute; come&ccedil;ando a mudar com algumas iniciativas, ainda que modestas, em ambos os setores.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><i><b>A Rede de Terapia G&ecirc;nica</b></i></font></p>     <p><font size="2" face="Verdana">A partir de 2005, come&ccedil;ou a ser organizada no Brasil uma Rede de Terapia G&ecirc;nica. Essa rede, coordenada pelo autor, congregou inicialmente 14 grupos de pesquisa de tr&ecirc;s Estados (Rio de Janeiro, S&atilde;o Paulo e Rio Grande do Sul), dedicados &agrave; pesquisa na &aacute;rea de terapia g&ecirc;nica e vacinas de DNA. Os estudos envolvem desenvolvimento de vetores virais, pesquisa b&aacute;sica e testes pr&eacute;&#45;cl&iacute;nicos nas &aacute;reas de c&acirc;ncer, doen&ccedil;as gen&eacute;ticas, doen&ccedil;as neurodegenerativas e vacinas de DNA para dengue, doen&ccedil;a de Chagas, infec&ccedil;&otilde;es por estreptococos e c&acirc;ncer. </font></p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">Um primeiro ensaio cl&iacute;nico de terapia g&ecirc;nica para revasculariza&ccedil;&atilde;o mioc&aacute;rdica com emprego de vetores plasmidiais contendo o gene do VEGF (<I>Vascular Endothelial Growth Factor</I>), promovido conjuntamente pelo Instituto de Cardiologia do Rio Grande do Sul, pela Funda&ccedil;&atilde;o de Amparo &agrave; Pesquisa do Rio Grande do Sul e pela Rede de Terapia G&ecirc;nica, por meio do Programa dos Institutos do Mil&ecirc;nio do MCT/CNPq, iniciou&#45;se em fevereiro de 2009 em Porto Alegre (<a href="http://clinicaltrials.gov/ct2/show/NCT00744315" target="_blank">http://clinicaltrials.gov/ct2/show/NCT00744315</a>). Trata&#45;se do primeiro ensaio cl&iacute;nico de terapia g&ecirc;nica sediado na Am&eacute;rica do Sul, em meio a dezenas de ensaios cl&iacute;nicos promovidos por empresas multinacionais ou institui&ccedil;&otilde;es de pesquisa estrangeiras que contam com participa&ccedil;&atilde;o de pesquisadores sul&#45;americanos (<a href="#tab07">Tabela 7</a>).</font></p>     <p><a name="tab07"></a></p>     <p>&nbsp;</p>     <p align="center"><img src="/img/revistas/ea/v24n70/a04tab07.jpg"></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Terapia g&ecirc;nica e biotecnologia no Brasil</b></font></p>     <p><font size="2" face="Verdana">Consistente com a incipiente presen&ccedil;a da pesquisa em terapia g&ecirc;nica, &eacute; reduzido o interesse do setor privado nessa &aacute;rea no pa&iacute;s. Recentemente, no entanto, foi instalada uma empresa sediada na Funda&ccedil;&atilde;o Parque de Alta Tecno&#45;logia de Petr&oacute;polis, no Estado do Rio de Janeiro, que, entre outros servi&ccedil;os de natureza biotecnol&oacute;gica, est&aacute; come&ccedil;ando a oferecer suporte para ensaios de terapia g&ecirc;nica no pa&iacute;s.</font></p>     <p><font size="2" face="Verdana">O vetor para o ensaio cl&iacute;nico de revasculariza&ccedil;&atilde;o mioc&aacute;rdica, iniciado em Porto Alegre, foi produzido por essa empresa de servi&ccedil;os, um evento pioneiro no pa&iacute;s e pren&uacute;ncio de novas parcerias entre o setor privado e institui&ccedil;&otilde;es acad&ecirc;micas nessa &aacute;rea de investiga&ccedil;&atilde;o cient&iacute;fica.</font></p>     <p><font size="2" face="Verdana">Por sua vez, a consci&ecirc;ncia do papel crucial dos mecanismos de prote&ccedil;&atilde;o &agrave; propriedade intelectual nessa &aacute;rea vem criando h&aacute;bitos em pesquisadores antes desacostumados com a preocupa&ccedil;&atilde;o em patentear produtos e processos de interesse biotecnol&oacute;gico. Assim, a atua&ccedil;&atilde;o da Rede de Terapia G&ecirc;nica tamb&eacute;m estimulou o primeiro dep&oacute;sito internacional de patente em terapia g&ecirc;nica <I>sensu stricto</I> efetuado por uma institui&ccedil;&atilde;o brasileira, consequente &agrave; pesquisa no laborat&oacute;rio do autor (World Intellectual Property Organization &#150; WO2009/121157 &#150; PCT/BR2009/000093).</font></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font size="3" face="Verdana"><b>Conclus&atilde;o</b></font></p>     <p><font size="2" face="Verdana">Ainda estamos no limiar da hist&oacute;ria da terapia g&ecirc;nica e tudo o que se fez at&eacute; hoje s&atilde;o os primeiros passos de uma longa e tortuosa caminhada (Flotte, 2007). Mas j&aacute; h&aacute; alguns sucessos pontuais que demonstram a viabilidade de incorpora&ccedil;&atilde;o da terapia g&ecirc;nica &agrave; pr&aacute;tica m&eacute;dica. Os principais avan&ccedil;os, at&eacute; o momento, encontram&#45;se nas &aacute;reas de hemofilia, alguns tipos de c&acirc;ncer, s&iacute;ndromes de imunodefici&ecirc;ncia combinada severa e certas retinopatias.</font></p>     <p><font size="2" face="Verdana">Tem havido grande progresso no planejamento e na constru&ccedil;&atilde;o de novos vetores mais seguros e eficientes (R&auml;ty et al., 2008). Em particular, as respostas imunit&aacute;rias dos pacientes est&atilde;o sendo estudadas em profundidade, novos modelos de estudo em animais v&ecirc;m sendo desenvolvidos e a pesquisa est&aacute; avan&ccedil;ando no sentido de aumentar a seguran&ccedil;a dos ensaios cl&iacute;nicos.</font></p>     <p><font size="2" face="Verdana">Os problemas n&atilde;o s&atilde;o triviais. Basta lembrar que, depois de todo o progresso da medicina at&eacute; os dias de hoje, apesar do sucesso que se obteve em novos tratamentos e na preven&ccedil;&atilde;o de tantas doen&ccedil;as nos &uacute;ltimos 150 anos, ainda lutamos contra doen&ccedil;as incur&aacute;veis, que desafiam a imagina&ccedil;&atilde;o e a compet&ecirc;ncia cient&iacute;fica e tecnol&oacute;gica de todo o mundo cient&iacute;fico. </font></p>     <p><font size="2" face="Verdana">H&aacute;, no entanto, raz&otilde;es para otimismo e a expectativa de sucesso das tecnologias de terapia g&ecirc;nica vem aumentando paulatinamente. Um sinal da viabilidade de aplica&ccedil;&atilde;o de terapia g&ecirc;nica em futuro pr&oacute;ximo &eacute; o investimento crescente que empresas de biotecnologia est&atilde;o fazendo no desenvolvimento e na submiss&atilde;o de pedidos de libera&ccedil;&atilde;o de produtos biol&oacute;gicos relativos &agrave; terapia g&ecirc;nica. </font></p>     <p><font size="2" face="Verdana">O Brasil prepara&#45;se para participar do advento da terapia g&ecirc;nica na pr&aacute;tica m&eacute;dica. O contingente de cientistas, t&eacute;cnicos, m&eacute;dicos e empres&aacute;rios envolvidos nesse campo no pa&iacute;s ainda &eacute; min&uacute;sculo, comparado aos pa&iacute;ses do Primeiro Mundo. Mas a decis&atilde;o de investir nessa &aacute;rea, tanto do ponto de vista financeiro quanto do ponto de vista cient&iacute;fico e educacional, seguramente ter&aacute; retorno significativo para a medicina brasileira do s&eacute;culo XXI.</font></p>     <p>&nbsp;</p>     <p><font size="3" face="Verdana"><b>Refer&ecirc;ncias</b></font></p>     <!-- ref --><p><font size="2" face="Verdana">AIUTI, A. et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. <I>N. Engl. J. Med</I>., v.360, n.5, p.447&#45;58, 2009.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000241&pid=S0103-4014201000030000400001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">AIUTI, A.; RONCAROLO, M. G. Ten years of gene therapy for primary immune deficiencies. <I>Hematology Am. Soc. Hematol. Educ. Program,</I> p.682&#45;9, 2009.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000243&pid=S0103-4014201000030000400002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">ANDERSON, W. F. Human gene therapy: the initial concepts. In: BRIGHAM, K. L. (Ed.) <I>Gene therapy for diseases of the lung</I>. S. l.: CRC Press, 1990. p.3&#45;16.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000245&pid=S0103-4014201000030000400003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     <!-- ref --><p><font size="2" face="Verdana">ANDERSON, W. F. et al. The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol.<I> Hum. Gene Ther</I>., v.1, n.3, p.331&#45;62, 1990.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000247&pid=S0103-4014201000030000400004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">ANDREWES, C. Richard Edwin Shope. In: <I>Biographical memoirs</I>. s. l.: National Academy of Sciences, 1979. v.50, p.352&#45;75.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000249&pid=S0103-4014201000030000400005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <p><font size="2" face="Verdana">ANDREWES, C. H. Rhinoviruses and common colds. <I>Annu. Rev. Med.</I>, v.17 p.361&#45;70, 1966.</font></p>     <p><font size="2" face="Verdana">ATKINS, G. J. et al. Therapeutic and prophylactic applications of alphavirus vectors. <I>Expert Rev. Mol. Med</I>., v.10, p.e33, 2008. </font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">BAGLEY, J. et al. Gene therapy in type 1 diabetes. <I>Crit. Rev. Immunol</I>., v.28, n.4, p.301&#45;24, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000253&pid=S0103-4014201000030000400008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">BAINBRIDGE, J. W. et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. <I>N. Engl. J. Med</I>., v.358, n.21, p.2231&#45;9, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000255&pid=S0103-4014201000030000400009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <p><font size="2" face="Verdana">BAUZON, M.; HERMISTON, T. W. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses. <I>Curr. Opin. Mol. Ther</I>., v.10, n.4, p.350&#45;5, 2008.</font></p>     <!-- ref --><p><font size="2" face="Verdana">BERETA, G. et al. Impact of retinal disease&#45;associated RPE65 mutations on retinoid  isomerization. <I>Biochemistry</I>, v.47, n.37, p.9856&#45;65, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000258&pid=S0103-4014201000030000400011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">BLAESE, R. M. et al. T lymphocyte&#45;directed gene therapy for ADA&#45;SCID: initial trial results after 4 years. <I>Science</I>, v.270, n.5235, p.475&#45;80, 1995.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000260&pid=S0103-4014201000030000400012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">BOBROW, M.; THOMAS, S. Patenting DNA. <I>Curr. Opin. Mol. Ther</I>., v.4, n.6, p.542&#45;7, 2002.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000262&pid=S0103-4014201000030000400013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">BRAAK, H.; DEL TREDICI, K. Assessing fetal nerve cell grafts in Parkinson's disease. <I>Nat. Med</I>., v.14, n.5, p.483&#45;5, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000264&pid=S0103-4014201000030000400014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">BRINKMAN, R. R. et al. Human monogenic disorders &#150; a source of novel drug targets. <I>Nat. Rev. Genet</I>., v.7, n.4, p.249&#45;60, 2006.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000266&pid=S0103-4014201000030000400015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">BUCKLEY, R. H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. <I>Annu. Rev. Immunol</I>., v.22, p.625&#45;55, 2004.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000268&pid=S0103-4014201000030000400016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">CACABELOS, R. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic&#45;related effects of multifactorial treatments on cognition, anxiety and  depression. <I>Methods Find Exp. Clin. Pharmacol</I>., v.29, Suppl A, p.1&#45;91, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000270&pid=S0103-4014201000030000400017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">CARDONE, M. Prospects for gene therapy in inherited neurodegenerative diseases. <I>Curr. Opin. Neurol</I>., v.20, n.2, p.151&#45;8, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000272&pid=S0103-4014201000030000400018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     <p><font size="2" face="Verdana">CATTANEO, R. et al. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. <I>Nat. Rev. Microbiol.</I>, v.6, n.7, p.529&#45;40, 2008. </font></p>     <!-- ref --><p><font size="2" face="Verdana">CAVAZZANA&#45;CALVO, M.; FISCHER, A. Gene therapy for severe combined immunodeficiency: are we there yet? <I>J. Clin. Invest.</I>, v.117, n.6, p.1456&#45;65, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000275&pid=S0103-4014201000030000400020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">CEMAZAR, M.; SERSA, G. Electrotransfer of therapeutic molecules into tissues. <I>Curr. Opin. Mol. Ther</I>., v.9, n.6, p.554&#45;62, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000277&pid=S0103-4014201000030000400021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">CHEN, Q. et al. Gene therapy for Parkinson's disease: progress and challenges. <I>Curr. Gene Ther</I>., v.5, p.71&#45;80, 2005.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000279&pid=S0103-4014201000030000400022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">CHRISTINE, C. W. et al.. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. <I>Neurology</I>, v.73, n.20, p.1662&#45;9, 2009.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000281&pid=S0103-4014201000030000400023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">CIDECIYAN, A. V. et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. <I>Proc. Natl. Acad. Sci. USA</I>, v.105, n.39, p.15112&#45;7, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000283&pid=S0103-4014201000030000400024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">CLANCHY, F. I.; WILLIAMS, R. O. Plasmid DNA as a safe gene delivery vehicle for treatment of chronic inflammatory disease. <I>Expert Opin. Biol. Ther</I>., v.8, n.10, p.1507&#45;19, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000285&pid=S0103-4014201000030000400025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     <!-- ref --><p><font size="2" face="Verdana">COLEMAN, W. B.; TSONGALIS, G. J. (Ed.) <I>Molecular pathology</I>: the molecular basis of human disease. S. l.: Academic Press, 2009. 664p.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000287&pid=S0103-4014201000030000400026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">CULVER, K. W. et al. Correction of ADA deficiency in human T lymphocytes using retroviral&#45;mediated gene transfer. <I>Transplant Proc</I>., v.23, n.1 Pt. 1, p.170&#45;1, 1991.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000289&pid=S0103-4014201000030000400027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">DASS, C. R. Lipoplex&#45;mediated delivery of nucleic acids: factors affecting in vivo transfection. <I>J. Mol. Med</I>., v.82, n.9, p.579&#45;91, 2004.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000291&pid=S0103-4014201000030000400028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">DAUER, W.; PRZEDBORSKI, S. Parkinson's disease: mechanisms and models. <I>Neuron</I>, v.39, p.889&#45;909, 2003.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000293&pid=S0103-4014201000030000400029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">DAWSON, T. M.; DAWSON, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. <I>Science</I>, v.302, p.819&#45;22, 2003.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000295&pid=S0103-4014201000030000400030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">HOLLANDER, A. I. den et al. FP Leber congenital amaurosis: genes, proteins and disease mechanisms. <I>Prog. Retin Eye Res</I>., v.27, n.4, p.391&#45;419, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000297&pid=S0103-4014201000030000400031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">DIAMOND, A.; JANKOVIC, J. The effect of deep brain stimulation on quality of life in movement disorders. <I>J. Neurol. Neurosurg Psychiatry</I>, v.76, p.1188&#45;93, 2005.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000299&pid=S0103-4014201000030000400032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">DORMOND, E. et al. From the first to the third generation adenoviral vector: what parameters are governing the production yield? <I>Biotechnol. Adv.</I>, v.27, n.2, p.133&#45;44, 2009.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000301&pid=S0103-4014201000030000400033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">EINSTEIN, O.; BEN&#45;HUR, T. The changing face of neural stem cell therapy in neurologic diseases. <I>Arch. Neurol.</I>, v.65, n.4, p.452&#45;6, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000303&pid=S0103-4014201000030000400034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">EVAN, G.; LITTLEWOOD, T. A matter of life and cell death. <I>Science</I>, v.281, n.5381, p.1317&#45;22, 1998.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000305&pid=S0103-4014201000030000400035&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">FAVARD, C. et al. Electrotransfer as a non viral method of gene delivery. <I>Curr. Gene Ther</I>., v.7, n.1, p.67&#45;77, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000307&pid=S0103-4014201000030000400036&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">FISCHER, A.; CAVAZZANA&#45;CALVO, M Gene therapy of inherited diseases. <I>Lancet</I>, v.371, n.9629, p.2044&#45;7, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000309&pid=S0103-4014201000030000400037&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">FJORD&#45;LARSEN, L. et al. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. <I>Exp. Neurol</I>., v.195, p.49&#45;60, 2005.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000311&pid=S0103-4014201000030000400038&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">FLOTTE, T. R. Gene therapy: the first two decades and the current state&#45;of&#45;the&#45;art. <I>J. Cell Physiol</I>., v.213, n.2, p.301&#45;5, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000313&pid=S0103-4014201000030000400039&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     <!-- ref --><p><font size="2" face="Verdana">FRIEDMANN T. The road toward human gene therapy&#45;&#45;a 25&#45;year perspective. <I>Ann Med</I>., v.29 n.6 p.575&#45;7, 1997.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000315&pid=S0103-4014201000030000400040&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">FRIEDMANN, T. Stanfield Rogers: insights into virus vectors and failure of an early gene therapy model. <I>Mol. Ther.</I>, v.4, n.4, p.285&#45;8, 2001.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000317&pid=S0103-4014201000030000400041&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">GASPAR, H. B. et al. Gene therapy of X&#45;linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. <I>Lancet</I>, v.364, n.9452, p.2181&#45;7, 2004.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000319&pid=S0103-4014201000030000400042&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">GAUTHIER, S.; POIRIER, J. Current and future management of Alzheimer's disease. <I>Alzheimers Dement</I>., v.4, n.1, Suppl. 1, p.S48&#45;50, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000321&pid=S0103-4014201000030000400043&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">GILL, D. R. et al. Progress and prospects: the design and production of plasmid vectors. <I>Gene Ther</I>., v.16, n.2, p.165&#45;71, 2009.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000323&pid=S0103-4014201000030000400044&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">GOLDSTEIN, M. Decade of the brain: an agenda for the nineties. <I>West. J. Med</I>., v.161, p.239&#45;41, 1994.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000325&pid=S0103-4014201000030000400045&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">GREEN, D. R.; EVAN, G. I. A matter of life and death. <I>Cancer Cell</I>., v.1, n.1, p.19&#45;30, 2002.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000327&pid=S0103-4014201000030000400046&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">GRIBBEN, J. G. Stem cell transplantation in chronic lymphocytic leukemia. <I>Biol. Blood Marrow Transplant</I>., v.15, n.1, Suppl., p.53&#45;8, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000329&pid=S0103-4014201000030000400047&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">GUTTMAN, M. et al. Current concepts in the diagnosis and management of Parkinson's disease. <I>CMAJ</I>, v.168, p.293&#45;301, 2003.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000331&pid=S0103-4014201000030000400048&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">HACEIN&#45;BEY&#45;ABINA, S. et al. Gene therapy of X&#45;linked severe combined immunodeficiency. <I>Int. J. Hematol</I>., v.76, n.4, p.295&#45;8, 2002.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000333&pid=S0103-4014201000030000400049&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     <!-- ref --><p><font size="2" face="Verdana">HACEIN&#45;BEY&#45;ABINA, S. et al. LMO2&#45;associated clonal T cell proliferation in two patients after gene therapy for SCID&#45;X1. <I>Science</I>, v.302, n.5644, p.415&#45;9, 2003.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000335&pid=S0103-4014201000030000400050&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">HAN, J. J.; MCDONALD, C. M. Diagnosis and clinical management of spinal muscular atrophy. <I>Phys. Med. Rehabil. Clin. N. Am</I>., v.19, n.3, p.661&#45;80, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000337&pid=S0103-4014201000030000400051&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">HASBROUCK, N. C.; HIGH, K. A. AAV&#45;mediated gene transfer for the treatment of hemophilia B: problems and prospects. <I>Gene Ther</I>., v.15, n.11, p.870&#45;5, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000339&pid=S0103-4014201000030000400052&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">HAUSER, O. et al. Encapsulated, genetically modified cells producing in vivo therapeutics. <I>Curr. Opin. Mol. Ther</I>., v.6, n.4, p.412&#45;20, 2004.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000341&pid=S0103-4014201000030000400053&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">HAUSWIRTH. W. et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno&#45;associated virus gene vector: short&#45;term results of a phase I trial. <I>Hum. Gene Ther</I>., v.19, n.10, p.979&#45;90, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000343&pid=S0103-4014201000030000400054&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">HERWEIJER, H.; WOLFF, J. A. Gene therapy progress and prospects: hydrodynamic gene delivery. <I>Gene Ther</I>., v.14, n.2, p.99&#45;107, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000345&pid=S0103-4014201000030000400055&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">HOWE, S. J. et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID&#45;X1 patients. <I>J. Clin Invest</I>., v.118, n.9, p.3143&#45;50, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000347&pid=S0103-4014201000030000400056&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">IMMONEN, A. et al. AdvHSV&#45;tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. <I>Mol. Ther.</I>, v.10, n.5, p.967&#45;72, 2004.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000349&pid=S0103-4014201000030000400057&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">JACKSON D. A.; SYMONS R. H., BERG, P. Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc. Natl. Acad. Sci. USA. v.69 n.10 p.2904&#45;9, 1972.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000351&pid=S0103-4014201000030000400058&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">JALBERT, J. J. et al. Dementia of the Alzheimer type. <I>Epidemiol. Rev</I>., v.30, p.15&#45;34, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000353&pid=S0103-4014201000030000400059&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">KANG, U. J. et al. Gene therapy for Parkinson's disease: determining the genes necessary for optimal dopamine replacement in rat models. <I>Hum. Cell.</I>, v.14, n.1, p.39&#45;48, 2001.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000355&pid=S0103-4014201000030000400060&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">KAPLITT, M. G. et al. Safety and tolerability of gene therapy with an adeno&#45;associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. <I>Lancet</I>, v.369, n.9579, p.2097&#45;105, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000357&pid=S0103-4014201000030000400061&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">KOHN, D. B.; CANDOTTI, F. Gene therapy fulfilling its promise. <I>N. Engl. J. Med.</I>, v.360, n.5, p.518&#45;21, 2009.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000359&pid=S0103-4014201000030000400062&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">KORDOWER, J. H. et al. Lewy body&#45;like pathology in long&#45;term embryonic nigral transplants in Parkinson's disease. <I>Nat. Med</I>., v.14, n.5, p.504&#45;6, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000361&pid=S0103-4014201000030000400063&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">LANDER, E. S. et al. Initial sequencing and analysis of the human genome. <I>Nature</I>, v.409, n.6822, p.860&#45;921, 2001.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000363&pid=S0103-4014201000030000400064&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">LI, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host&#45;to&#45;graft disease propagation. <I>Nat. Med.</I>, v.14, n.5, p.501&#45;3, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000365&pid=S0103-4014201000030000400065&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">LINDEN, R. <I>Genes contra doen&ccedil;as</I>. Terapia g&ecirc;nica: uma nova era na gen&eacute;tica. Rio de Janeiro: Vieira e Lent, 2008. 128p.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000367&pid=S0103-4014201000030000400066&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">LINDEN,  R.; LENZ, G. Terapia g&ecirc;nica em neurologia. In: MORALES, M. M. (Ed.) <I>Terapias avan&ccedil;adas</I>. Rio de Janeiro: Atheneu, 2007. p.205&#45;22.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000369&pid=S0103-4014201000030000400067&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     <!-- ref --><p><font size="2" face="Verdana">LINDVALL, O.; WAHLBERG, L. U. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? <I>Exp. Neurol</I>., v.209, n.1, p.82&#45;8, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000371&pid=S0103-4014201000030000400068&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">LUNDBERG, C. et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. <I>Curr. Gene Ther</I>., v.8, n.6, p.461&#45;73, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000373&pid=S0103-4014201000030000400069&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">LUO J. et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. <I>Science</I>, v.298, p.425&#45;9, 2002.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000375&pid=S0103-4014201000030000400070&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     <!-- ref --><p><font size="2" face="Verdana">MACHIDA, C. A. (Ed.) <I>Viral vectors for gene therapy</I>: methods and protocols. S. l.: Humana Press, 2002. 608p.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000377&pid=S0103-4014201000030000400071&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">MAGUIRE, A. M. et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. <I>N. Engl. J. Med</I>., v.358, n.21, p.2240&#45;8, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000379&pid=S0103-4014201000030000400072&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">MANNO, C. S. et al. AAV&#45;mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. <I>Blood</I>, v.101, n.8, p.2963&#45;72, 2003.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000381&pid=S0103-4014201000030000400073&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">MANNO, C. S. et al. Successful transduction of liver in hemophilia by AAV&#45;Factor IX and limitations imposed by the host immune response. <I>Nat. Med</I>., v.12, n.3, p.342&#45;7, 2006.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000383&pid=S0103-4014201000030000400074&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     <!-- ref --><p><font size="2" face="Verdana">MARKS, W. J. et al. Safety and tolerability of intraputaminal delivery of CERE&#45;120 (adeno&#45;associated virus serotype 2&#45;neurturin) to patients with idiopathic Parkinson's disease: an open&#45;label, phase I trial. <I>Lancet Neurol</I>., v.7, n.5, p.400&#45;8, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000385&pid=S0103-4014201000030000400075&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">MENDEZ, I. et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. <I>Nat. Med.</I>, v.14, n.5, p.507&#45;9, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000387&pid=S0103-4014201000030000400076&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">MERCOLA, K. E.; CLINE, M. J. Sounding boards. The potentials of inserting new genetic information. <I>N. Engl. J. Med</I>., v.303, n.22, p.1297&#45;300, 1980.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000389&pid=S0103-4014201000030000400077&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">MINGOZZI, F.; HIGH, K. A. Immune responses to AAV in clinical trials. <I>Curr. Gene Ther</I>., v.7, n.5, p.316&#45;24, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000391&pid=S0103-4014201000030000400078&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">MULLEN C. A. et al. Molecular analysis of T lymphocyte&#45;directed gene therapy for adenosine deaminase deficiency: long&#45;term expression in vivo of genes introduced with a retroviral vector. <I>Hum. Gene Ther.</I>, v.7 n.9 p.1123&#45;9, 1996.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000393&pid=S0103-4014201000030000400079&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">MUUL, L. M. et al.  Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long&#45;term results of the first clinical gene therapy trial. <I>Blood</I>, v.101, n.7, p.2563&#45;9, 2003.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000395&pid=S0103-4014201000030000400080&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">NAKANO, K. Neural circuits and topographic organization of the basal ganglia and related regions. <I>Brain Dev</I>., v.22, Suppl. 1, p.S5&#45;16, 2000.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000397&pid=S0103-4014201000030000400081&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">NATHWANI, A. C. et al. A review of gene therapy for haematological disorders. <I>Br. J. Haematol.,</I> v.28, n.1, p.3&#45;17, 2005.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000399&pid=S0103-4014201000030000400082&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">NCBI. Genes and disease. 2009. Dispon&iacute;vel em: &lt;<a href="http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=gnd&amp;ref=sidebar" target="_blank">http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=gnd&ref=sidebar</a>&gt;    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000401&pid=S0103-4014201000030000400083&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref -->.</font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">O'CONNOR, T. P.; CRYSTAL, R. G. Genetic medicines: treatment strategies for hereditary disorders. <I>Nat. Rev. Genet</I>., v.7, n.4, p.261&#45;76, 2006.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000403&pid=S0103-4014201000030000400084&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">OLANOW, C. W. et al. Why have we failed to achieve neuroprotection in Parkinson's disease? <I>Ann Neurol.</I>, v.64 Suppl 2,p.S101&#45;10, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000405&pid=S0103-4014201000030000400085&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     <!-- ref --><p><font size="2" face="Verdana">PARDRIDGE, W. M. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. <I>NeuroRx</I>., v.2, n.1, p.129&#45;38, 2005.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000407&pid=S0103-4014201000030000400086&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">PARDRIDGE, W. M. Blood&#45;brain barrier delivery of protein and non&#45;viral gene therapeutics with molecular Trojan horses. <I>J. Control. Release</I>, v.122, n.3, p.345&#45;8, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000409&pid=S0103-4014201000030000400087&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">PEARSON, S. et al. China approves first gene therapy. <I>Nature Biotechnol</I>., v.22, p.3&#45;4, 2004.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000411&pid=S0103-4014201000030000400088&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">PHACILITATE, Inc. 5th Annual Cell and Gene Therapy Forum. Washington, DC, 26&#45;28 January, 2009.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000413&pid=S0103-4014201000030000400089&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">POEHNER, W. J. et al.  A homozygous deletion in RPE65 in a small Sardinian family with autosomal recessive retinal dystrophy. <I>Mol. Vis</I>., v.6, p.192&#45;8, 2000.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000415&pid=S0103-4014201000030000400090&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">POEWE, W. Treatments for Parkinson disease &#45; past achievements and current clinical needs. <I>Neurology</I>, v.72, n.7, Supp. p.S65&#45;73, 2009.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000417&pid=S0103-4014201000030000400091&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">PORTEUS, M. H. et al. A look to future directions in gene therapy research for monogenic diseases. <I>PLoS Genet</I>., v.2, n.9, p.e133, 2006.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000419&pid=S0103-4014201000030000400092&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     <!-- ref --><p><font size="2" face="Verdana">PROCHOWNIK, E. V. c&#45;Myc: linking transformation and genomic instability. <I>Curr. Mol. Med</I>., v.8, n.6, p.446&#45;58, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000421&pid=S0103-4014201000030000400093&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">RADUNOVIC, A. et al. Clinical care of patients with amyotrophic lateral sclerosis. <I>Lancet Neurol</I>., v.6, n.10, p.913&#45;25, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000423&pid=S0103-4014201000030000400094&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">RAINOV, N. G.; REN, H. Gene therapy for human malignant brain tumors. <I>Cancer J.</I>, v.9, n.3, p.180&#45;8, 2003.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000425&pid=S0103-4014201000030000400095&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">RAPER, S. E. et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. <I>Mol. Genet. Metab</I>., v.80, n.1&#45;2, p.148&#45;58, 2003.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000427&pid=S0103-4014201000030000400096&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">RAPER, S. E. et al. Developing adenoviral&#45;mediated in vivo gene therapy for ornithine  transcarbamylase deficiency. <I>J. Inherit Metab. Dis</I>., v.21, Suppl. 1, p.119&#45;37, 1998.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000429&pid=S0103-4014201000030000400097&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">R&Auml;TY, J. K. et al. Improving safety of gene therapy. <I>Curr. Drug Saf</I>., v.3, n.1, p.46&#45;53, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000431&pid=S0103-4014201000030000400098&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">REFFELMANN, T. et al. Promise of blood&#45; and bone marrow&#45;derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. <I>J. Am. Coll. Cardiol</I>., v.53, n.4, p.305&#45;8, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000433&pid=S0103-4014201000030000400099&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">RIBACKA, C. et al. Cancer, stem cells, and oncolytic viruses. <I>Ann. Med</I>., v.40, n.7, p.496&#45;505, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000435&pid=S0103-4014201000030000400100&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">ROGERS, S.; ROUS, P. Joint action of a chemical carcinogen and a neoplastic virus to induce cancer in rabbits; results of exposing epidermal cells to a carcinogenic hydrocarbon at time of infection with the Shope papilloma virus. <I>J. Exp. Med</I>., v.93, n.5, p.459&#45;88, 1951.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000437&pid=S0103-4014201000030000400101&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">ROGERS, S. Serial transplantation of rabbit papillomas caused by the Shope virus. <I>J. Exp. Med</I>., v.95, n.6, p.543&#45;54, 1952.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000439&pid=S0103-4014201000030000400102&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">SANVICENS, N.; MARCO, M. P. Multifunctional nanoparticles&#45;&#45;properties and prospects for their use in human medicine. <I>Trends Biotechnol</I>., v.26, n.8, p.425&#45;33, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000441&pid=S0103-4014201000030000400103&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">SCAGLIA, F.; LEE, B. Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency. <I>Am. J. Med. Genet. C. Semin. Med. Genet</I>., v.142C, n.2, p.113&#45;20, 2006.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000443&pid=S0103-4014201000030000400104&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">SILVA, C. L. et al. Recent advances in DNA vaccines for autoimmune diseases. <I>Expert Rev. Vaccines</I>, v.8, n.2, p.239&#45;52, 2009.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000445&pid=S0103-4014201000030000400105&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">SYKES, K. Progress in the development of genetic immunization. <I>Expert Rev. Vaccines</I>, v.7, n.9, p.1395&#45;404, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000447&pid=S0103-4014201000030000400106&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">THAJEB, P. et al. The effects of storage conditions and trophic supplementation on the survival of fetal mesencephalic cells. <I>Cell Transplant.</I>, v.6, p.297&#45;307, 1997.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000449&pid=S0103-4014201000030000400107&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">TORRENTE, Y.; POLLI, E. Mesenchymal stem cell transplantation for neurodegenerative diseases. <I>Cell Transplant</I>., v.17, n.10&#45;11, p.1103&#45;13, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000451&pid=S0103-4014201000030000400108&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">Van der SPUY, J. et al. Predominant rod photoreceptor degeneration in Leber congenital amaurosis. <I>Mol Vis</I>., v.11, p.542&#45;53, 2005.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000453&pid=S0103-4014201000030000400109&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">VAZQUEZ, A. et al. The genetics of the p53 pathway, apoptosis and cancer therapy. <I>Nat. Rev. Drug Discov</I>., v.7, n.12, p.979&#45;87, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000455&pid=S0103-4014201000030000400110&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">VELLAI, T.; VIDA, G. The origin of eukaryotes: the difference between prokaryotic and eukaryotic cells. <I>Proc. Biol. Sci</I>., v.266, n.1428, p.1571&#45;7, 1999.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000457&pid=S0103-4014201000030000400111&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">VENTER, J. C. et al. The sequence of the human genome. <I>Science</I>, v.291, n.5507, p.1304&#45;51, 2001.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000459&pid=S0103-4014201000030000400112&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">VOSS, C. Production of plasmid DNA for pharmaceutical use. <I>Biotechnol. Annu. Rev</I>., v.13, p.201&#45;22, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000461&pid=S0103-4014201000030000400113&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font size="2" face="Verdana">WANG, X. et al. Mitotic checkpoint defects in human cancers and their implications to chemotherapy. <I>Front Biosci</I>., v.13, p.2103&#45;14, 2008.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000463&pid=S0103-4014201000030000400114&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> </font></p>     <!-- ref --><p><font size="2" face="Verdana">WATSON, J. D. et al. <I>Recombinant DNA: genes and genomics: a short course</I>. S. l.:  Freeman, 2006. 474p.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000465&pid=S0103-4014201000030000400115&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">WU, C.; LU, Y. Inclusion of high molecular weight dextran in calcium phosphate&#45;mediated transfection significantly improves gene transfer efficiency. <I>Cell. Mol. Biol.</I>, Noisy&#45;le&#45;grand, v.53, n.4, p.67&#45;74, 2007.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000467&pid=S0103-4014201000030000400116&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <!-- ref --><p><font size="2" face="Verdana">YI, Y.; HAHM, S. H.; LEE, K. H. Retroviral gene therapy: safety issues and possible solutions. <I>Curr. Gene Ther.</I>, v.5 n.1 p.25&#45;35, 2005.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000469&pid=S0103-4014201000030000400117&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana">Recebido em 29.7.2010. Aceito em 17.8.2010.</font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font size="2" face="Verdana"><i>Rafael Linden </i>&eacute; m&eacute;dico, doutor em Ci&ecirc;ncias, professor titular do Instituto de Bio&#45;f&iacute;sica Carlos Chagas Filho, UFRJ.  @ <b>&#150; </b><a href="mailto:rlinden@biof.ufrj.br">rlinden@biof.ufrj.br</a></font></p>      ]]></body><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[AIUTI]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene therapy for immunodeficiency due to adenosine deaminase deficiency]]></article-title>
<source><![CDATA[N. Engl. J. Med.]]></source>
<year>2009</year>
<volume>360</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>447-58</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[AIUTI]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[RONCAROLO]]></surname>
<given-names><![CDATA[M. G.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Ten years of gene therapy for primary immune deficiencies]]></article-title>
<source><![CDATA[Hematology Am. Soc. Hematol. Educ. Program]]></source>
<year>2009</year>
<page-range>682-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ANDERSON]]></surname>
<given-names><![CDATA[W. F.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Human gene therapy: the initial concepts]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[BRIGHAM]]></surname>
<given-names><![CDATA[K. L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Gene therapy for diseases of the lung]]></source>
<year>1990</year>
<page-range>3-16</page-range><publisher-name><![CDATA[CRC Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ANDERSON]]></surname>
<given-names><![CDATA[W. F.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol]]></article-title>
<source><![CDATA[Hum Gene Ther]]></source>
<year>1990</year>
<volume>1</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>331-62</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ANDREWES]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Richard Edwin Shope]]></article-title>
<source><![CDATA[Biographical memoirs]]></source>
<year>1979</year>
<volume>50</volume>
<page-range>352-75</page-range><publisher-name><![CDATA[National Academy of Sciences]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ANDREWES]]></surname>
<given-names><![CDATA[C. H.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Rhinoviruses and common colds]]></article-title>
<source><![CDATA[Annu. Rev. Med.]]></source>
<year>1966</year>
<volume>17</volume>
<page-range>361-70</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ATKINS]]></surname>
<given-names><![CDATA[G .J.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Therapeutic and prophylactic applications of alphavirus vectors]]></article-title>
<source><![CDATA[Expert. Ver. Mol. Med.]]></source>
<year>2008</year>
<volume>10</volume>
<page-range>e33</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BAGLEY]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene therapy in type 1 diabetes]]></article-title>
<source><![CDATA[Crit. Rev. Immunol.]]></source>
<year>2008</year>
<volume>28</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>301-24</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BAINBRIDGE]]></surname>
<given-names><![CDATA[J. W.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of gene therapy on visual function in Leber's congenital amaurosis]]></article-title>
<source><![CDATA[N. Engl. J. Med.]]></source>
<year>2008</year>
<volume>358</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2231-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BAUZON]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[HERMISTON]]></surname>
<given-names><![CDATA[T. W.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses]]></article-title>
<source><![CDATA[Curr. Opin. Mol. Ther.]]></source>
<year>2008</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>350-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BERETA]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Impact of retinal disease-associated RPE65 mutations on retinoid isomerization]]></article-title>
<source><![CDATA[Biochemistry]]></source>
<year>2008</year>
<volume>47</volume>
<numero>37</numero>
<issue>37</issue>
<page-range>9856-65</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BLAESE]]></surname>
<given-names><![CDATA[R. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years]]></article-title>
<source><![CDATA[Science]]></source>
<year>1995</year>
<volume>270</volume>
<numero>5235</numero>
<issue>5235</issue>
<page-range>475-80</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BOBROW]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[THOMAS]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Patenting DNA]]></article-title>
<source><![CDATA[Curr. Opin. Mol. Ther.]]></source>
<year>2002</year>
<volume>4</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>542-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BRAAK]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[DEL]]></surname>
<given-names><![CDATA[TREDICI, K.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Assessing fetal nerve cell grafts in Parkinson's disease]]></article-title>
<source><![CDATA[Nat. Med.]]></source>
<year>2008</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>483-5</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BRINKMAN]]></surname>
<given-names><![CDATA[R. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Human monogenic disorders - a source of novel drug targets]]></article-title>
<source><![CDATA[Nat. Rev. Genet.]]></source>
<year>2006</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>249-60</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BUCKLEY]]></surname>
<given-names><![CDATA[R. H.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution]]></article-title>
<source><![CDATA[Annu. Rev. Immunol.]]></source>
<year>2004</year>
<volume>22</volume>
<page-range>625-55</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CACABELOS]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression]]></article-title>
<source><![CDATA[Methods Find Exp. Clin. Pharmacol.]]></source>
<year>2007</year>
<volume>29</volume>
<page-range>1-91</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CARDONE]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prospects for gene therapy in inherited neurodegenerative diseases]]></article-title>
<source><![CDATA[Curr. Opin. Neurol.]]></source>
<year>2007</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>151-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CATTANEO]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded]]></article-title>
<source><![CDATA[Nat. Ver. Microbiol.]]></source>
<year>2008</year>
<volume>6</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>529-40</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CAVAZZANA-CALVO]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[FISCHER]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene therapy for severe combined immunodeficiency: are we there yet]]></article-title>
<source><![CDATA[J. Clin. Invest.]]></source>
<year>2007</year>
<volume>117</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1456-65</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CEMAZAR]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[SERSA]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Electrotransfer of therapeutic molecules into tissues]]></article-title>
<source><![CDATA[Curr. Opin. Mol. Ther.]]></source>
<year>2007</year>
<volume>9</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>554-62</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CHEN]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene therapy for Parkinson's disease: progress and challenges]]></article-title>
<source><![CDATA[Curr. Gene Ther.]]></source>
<year>2005</year>
<volume>5</volume>
<page-range>71-80</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CHRISTINE]]></surname>
<given-names><![CDATA[C. W.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Safety and tolerability of putaminal AADC gene therapy for Parkinson disease]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2009</year>
<volume>73</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1662-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CIDECIYAN]]></surname>
<given-names><![CDATA[A. V.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics]]></article-title>
<source><![CDATA[Proc. Natl. Acad. Sci.]]></source>
<year>2008</year>
<volume>105</volume>
<numero>39</numero>
<issue>39</issue>
<page-range>15112-7</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CLANCHY]]></surname>
<given-names><![CDATA[F. I.]]></given-names>
</name>
<name>
<surname><![CDATA[WILLIAMS]]></surname>
<given-names><![CDATA[R. O.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Plasmid DNA as a safe gene delivery vehicle for treatment of chronic inflammatory disease]]></article-title>
<source><![CDATA[Expert Opin. Biol. Ther.]]></source>
<year>2008</year>
<volume>8</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1507-19</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[COLEMAN]]></surname>
<given-names><![CDATA[W. B.]]></given-names>
</name>
<name>
<surname><![CDATA[TSONGALIS]]></surname>
<given-names><![CDATA[G. J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Molecular pathology: the molecular basis of human disease]]></source>
<year>2009</year>
<publisher-name><![CDATA[Academic Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CULVER]]></surname>
<given-names><![CDATA[K. W.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer]]></article-title>
<source><![CDATA[Transplant Proc.]]></source>
<year>1991</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>170-1</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DASS]]></surname>
<given-names><![CDATA[C. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection]]></article-title>
<source><![CDATA[J. Mol. Med.]]></source>
<year>2004</year>
<volume>82</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>579-91</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DAUER]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[PRZEDBORSKI]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Parkinson's disease: mechanisms and models]]></article-title>
<source><![CDATA[Neuron]]></source>
<year>2003</year>
<volume>39</volume>
<page-range>889-909</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DAWSON]]></surname>
<given-names><![CDATA[T. M.]]></given-names>
</name>
<name>
<surname><![CDATA[DAWSON]]></surname>
<given-names><![CDATA[V. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Molecular pathways of neurodegeneration in Parkinson's disease]]></article-title>
<source><![CDATA[Science]]></source>
<year>2003</year>
<volume>302</volume>
<page-range>819-22</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HOLLANDER]]></surname>
<given-names><![CDATA[A. I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Prog. Retin Eye Res.FP Leber congenital amaurosis: genes, proteins and disease mechanisms]]></source>
<year>2008</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>391-419</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DIAMOND]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[JANKOVIC]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[J. Neurol. Neurosurg Psychiatry]]></source>
<year>2005</year>
<volume>76</volume>
<page-range>1188-93</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DORMOND]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[From the first to the third generation adenoviral vector: what parameters are governing the production yield]]></article-title>
<source><![CDATA[Biotechnol. Adv.]]></source>
<year>2009</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>133-44</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[EINSTEIN]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[BEN-HUR]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The changing face of neural stem cell therapy in neurologic diseases]]></article-title>
<source><![CDATA[Arch. Neurol.]]></source>
<year>2008</year>
<volume>65</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>452-6</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[EVAN]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[LITTLEWOOD]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A matter of life and cell death]]></article-title>
<source><![CDATA[Science]]></source>
<year>1998</year>
<volume>281</volume>
<numero>5381</numero>
<issue>5381</issue>
<page-range>1317-22</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FAVARD]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Electrotransfer as a non viral method of gene delivery]]></article-title>
<source><![CDATA[Curr. Gene. Ther.]]></source>
<year>2007</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>67-77</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FISCHER]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[CAVAZZANA-CALVO]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene therapy of inherited diseases]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2008</year>
<volume>371</volume>
<numero>9629</numero>
<issue>9629</issue>
<page-range>2044-7</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FJORD-LARSEN]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct]]></article-title>
<source><![CDATA[Exp. Neurol.]]></source>
<year>2005</year>
<volume>195</volume>
<page-range>49-60</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FLOTTE]]></surname>
<given-names><![CDATA[T. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene therapy: the first two decades and the current state-of-the-art]]></article-title>
<source><![CDATA[J. Cell. Physiol.]]></source>
<year>2007</year>
<volume>213</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>301-5</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FRIEDMANN]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The road toward human gene therapy--a 25-year perspective]]></article-title>
<source><![CDATA[Ann Med.]]></source>
<year>1997</year>
<volume>29</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>575-7</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<source><![CDATA[Mol Ther]]></source>
<year>2001</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>285-8</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GASPAR]]></surname>
<given-names><![CDATA[H. B.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2004</year>
<volume>364</volume>
<numero>9452</numero>
<issue>9452</issue>
<page-range>2181-7</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GAUTHIER]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[POIRIER]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Current and future management of Alzheimer's disease]]></article-title>
<source><![CDATA[Alzheimers Dement.]]></source>
<year>2008</year>
<volume>4</volume>
<numero>1, Suppl. 1</numero>
<issue>1, Suppl. 1</issue>
<page-range>S48-50</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GILL]]></surname>
<given-names><![CDATA[D. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Progress and prospects: the design and production of plasmid vectors]]></article-title>
<source><![CDATA[Gene Ther.]]></source>
<year>2009</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>165-71</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GOLDSTEIN]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Decade of the brain: an agenda for the nineties]]></article-title>
<source><![CDATA[West. J. Med.]]></source>
<year>1994</year>
<volume>161</volume>
<page-range>239-41</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GREEN]]></surname>
<given-names><![CDATA[D. R.]]></given-names>
</name>
<name>
<surname><![CDATA[EVAN]]></surname>
<given-names><![CDATA[G. I.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A matter of life and death.]]></article-title>
<source><![CDATA[Cancer Cell.]]></source>
<year>2002</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-30</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GRIBBEN]]></surname>
<given-names><![CDATA[J. G.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Stem cell transplantation in chronic lymphocytic leukemia]]></article-title>
<source><![CDATA[Biol. Blood Marrow Transplant.]]></source>
<year>2008</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>53-8</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GUTTMAN]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Current concepts in the diagnosis and management of Parkinson's disease]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2003</year>
<volume>168</volume>
<page-range>293-301</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HACEIN-BEY-ABINA]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene therapy of X-linked severe combined immunodeficiency]]></article-title>
<source><![CDATA[Int. J. Hematol.]]></source>
<year>2002</year>
<volume>76</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>295-8</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HACEIN-BEY-ABINA]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1]]></article-title>
<source><![CDATA[Science]]></source>
<year>2003</year>
<volume>302</volume>
<numero>5644</numero>
<issue>5644</issue>
<page-range>415-9</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HAN]]></surname>
<given-names><![CDATA[J. J.]]></given-names>
</name>
<name>
<surname><![CDATA[MCDONALD]]></surname>
<given-names><![CDATA[C. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diagnosis and clinical management of spinal muscular atrophy]]></article-title>
<source><![CDATA[Phys. Med. Rehabil. Clin. N. Am.]]></source>
<year>2008</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>661-80</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HASBROUCK]]></surname>
<given-names><![CDATA[N. C.]]></given-names>
</name>
<name>
<surname><![CDATA[HIGH]]></surname>
<given-names><![CDATA[K. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects]]></article-title>
<source><![CDATA[Gene Ther.]]></source>
<year>2008</year>
<volume>15</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>870-5</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HAUSER]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Encapsulated, genetically modified cells producing in vivo therapeutics]]></article-title>
<source><![CDATA[Curr. Opin. Mol. Ther]]></source>
<year>2004</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>412-20</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HAUSWIRTH]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial]]></article-title>
<source><![CDATA[Hum. Gene. Ther.]]></source>
<year>2008</year>
<volume>19</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>979-90</page-range></nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HERWEIJER]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[WOLFF]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene therapy progress and prospects: hydrodynamic gene delivery]]></article-title>
<source><![CDATA[Gene Ther.]]></source>
<year>2007</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>99-107</page-range></nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HOWE]]></surname>
<given-names><![CDATA[S. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients]]></article-title>
<source><![CDATA[J. Clin Invest.]]></source>
<year>2008</year>
<volume>118</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>3143-50</page-range></nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[IMMONEN]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study]]></article-title>
<source><![CDATA[Mol. Ther.]]></source>
<year>2004</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>967-72</page-range></nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[JACKSON]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
<name>
<surname><![CDATA[SYMONS]]></surname>
<given-names><![CDATA[R. H.]]></given-names>
</name>
<name>
<surname><![CDATA[BERG]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli]]></article-title>
<source><![CDATA[Proc. Natl. Acad. Sci]]></source>
<year>1972</year>
<volume>69</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2904-9</page-range></nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[JALBERT]]></surname>
<given-names><![CDATA[J. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Dementia of the Alzheimer type.]]></article-title>
<source><![CDATA[Epidemiol. Rev.]]></source>
<year>2008</year>
<volume>30</volume>
<page-range>15-34</page-range></nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KANG]]></surname>
<given-names><![CDATA[U. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene therapy for Parkinson's disease: determining the genes necessary for optimal dopamine replacement in rat models]]></article-title>
<source><![CDATA[Hum. Cell.]]></source>
<year>2001</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-48</page-range></nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KAPLITT]]></surname>
<given-names><![CDATA[M. G.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2007</year>
<volume>369</volume>
<numero>9579</numero>
<issue>9579</issue>
<page-range>2097-105</page-range></nlm-citation>
</ref>
<ref id="B62">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KOHN]]></surname>
<given-names><![CDATA[D. B.]]></given-names>
</name>
<name>
<surname><![CDATA[CANDOTTI]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene therapy fulfilling its promise]]></article-title>
<source><![CDATA[N. Engl. J. Med.]]></source>
<year>2009</year>
<volume>360</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>518-21</page-range></nlm-citation>
</ref>
<ref id="B63">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KORDOWER]]></surname>
<given-names><![CDATA[J. H.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nat]]></article-title>
<source><![CDATA[Med.]]></source>
<year>2008</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>504-6</page-range></nlm-citation>
</ref>
<ref id="B64">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LANDER]]></surname>
<given-names><![CDATA[E. S.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Initial sequencing and analysis of the human genome]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2001</year>
<volume>409</volume>
<numero>6822</numero>
<issue>6822</issue>
<page-range>860-921</page-range></nlm-citation>
</ref>
<ref id="B65">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LI]]></surname>
<given-names><![CDATA[J. Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation]]></article-title>
<source><![CDATA[Nat. Med.]]></source>
<year>2008</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>501-3</page-range></nlm-citation>
</ref>
<ref id="B66">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LINDEN]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Genes contra doenças: Terapia gênica: uma nova era na genética]]></source>
<year>2008</year>
<page-range>128p</page-range><publisher-loc><![CDATA[Rio de Janeiro ]]></publisher-loc>
<publisher-name><![CDATA[Vieira e Lent]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B67">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LINDEN]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[LENZ]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Terapia gênica em neurologia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[MORALES]]></surname>
<given-names><![CDATA[M. M.]]></given-names>
</name>
</person-group>
<source><![CDATA[]]></source>
<year>2007</year>
<page-range>205-22</page-range><publisher-loc><![CDATA[Rio de Janeiro ]]></publisher-loc>
<publisher-name><![CDATA[Atheneu]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B68">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LINDVALL]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[WAHLBERG]]></surname>
<given-names><![CDATA[L. U.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?]]></article-title>
<source><![CDATA[Exp. Neurol.]]></source>
<year>2008</year>
<volume>209</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>82-8</page-range></nlm-citation>
</ref>
<ref id="B69">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LUNDBERG]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Applications of lentiviral vectors for biology and gene therapy of neurological disorders]]></article-title>
<source><![CDATA[Curr. Gene Ther.]]></source>
<year>2008</year>
<volume>8</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>461-73</page-range></nlm-citation>
</ref>
<ref id="B70">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LUO]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Subthalamic GAD gene therapy in a Parkinson's disease rat model.]]></article-title>
<source><![CDATA[Science]]></source>
<year>2002</year>
<volume>298</volume>
<page-range>425-9</page-range></nlm-citation>
</ref>
<ref id="B71">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MACHIDA]]></surname>
<given-names><![CDATA[C. A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Viral vectors for gene therapy: methods and protocols]]></source>
<year>2002</year>
<publisher-name><![CDATA[Humana Press608]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B72">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MAGUIRE]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Safety and efficacy of gene transfer for Leber's congenital amaurosis]]></article-title>
<source><![CDATA[N. Engl. J. Med.]]></source>
<year>2008</year>
<volume>358</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2240-8</page-range></nlm-citation>
</ref>
<ref id="B73">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MANNO]]></surname>
<given-names><![CDATA[C. S.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2003</year>
<volume>101</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2963-72</page-range></nlm-citation>
</ref>
<ref id="B74">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MANNO]]></surname>
<given-names><![CDATA[C. S.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response]]></article-title>
<source><![CDATA[Nat. Med.]]></source>
<year>2006</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>342-7</page-range></nlm-citation>
</ref>
<ref id="B75">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MARKS]]></surname>
<given-names><![CDATA[W. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial]]></article-title>
<source><![CDATA[Lancet Neurol., v.7]]></source>
<year>2008</year>
<numero>5</numero>
<issue>5</issue>
<page-range>400-8</page-range></nlm-citation>
</ref>
<ref id="B76">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MENDEZ]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years.]]></article-title>
<source><![CDATA[Nat. Med.]]></source>
<year>2008</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>507-9</page-range></nlm-citation>
</ref>
<ref id="B77">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MERCOLA]]></surname>
<given-names><![CDATA[K. E.]]></given-names>
</name>
<name>
<surname><![CDATA[CLINE]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sounding boards. The potentials of inserting new genetic information]]></article-title>
<source><![CDATA[N. Engl. J. Med.]]></source>
<year>1980</year>
<volume>303</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>1297-300</page-range></nlm-citation>
</ref>
<ref id="B78">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MINGOZZI]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[HIGH]]></surname>
<given-names><![CDATA[K. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immune responses to AAV in clinical trials]]></article-title>
<source><![CDATA[Curr. Gene Ther.]]></source>
<year>2007</year>
<volume>7</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>316-24</page-range></nlm-citation>
</ref>
<ref id="B79">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MULLEN]]></surname>
<given-names><![CDATA[C. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector]]></article-title>
<source><![CDATA[Hum. Gene Ther.]]></source>
<year>1996</year>
<volume>7</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1123-9</page-range></nlm-citation>
</ref>
<ref id="B80">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MUUL]]></surname>
<given-names><![CDATA[L. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2003</year>
<volume>101</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2563-9</page-range></nlm-citation>
</ref>
<ref id="B81">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[NAKANO]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neural circuits and topographic organization of the basal ganglia and related regions]]></article-title>
<source><![CDATA[Brain Dev.]]></source>
<year>2000</year>
<volume>22, Suppl. 1</volume>
<page-range>S5-16</page-range></nlm-citation>
</ref>
<ref id="B82">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[NATHWANI]]></surname>
<given-names><![CDATA[A. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A review of gene therapy for haematological disorders]]></article-title>
<source><![CDATA[Br. J. Haematol.]]></source>
<year>2005</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-17</page-range></nlm-citation>
</ref>
<ref id="B83">
<nlm-citation citation-type="">
<collab>NCBI</collab>
<source><![CDATA[Genes and disease.]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B84">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'CONNOR]]></surname>
<given-names><![CDATA[T. P.]]></given-names>
</name>
<name>
<surname><![CDATA[CRYSTAL]]></surname>
<given-names><![CDATA[R. G.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Genetic medicines: treatment strategies for hereditary disorders]]></article-title>
<source><![CDATA[Nat. Rev. Genet.]]></source>
<year>2006</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>261-76</page-range></nlm-citation>
</ref>
<ref id="B85">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[OLANOW]]></surname>
<given-names><![CDATA[C. W.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Why have we failed to achieve neuroprotection in Parkinson's disease?]]></article-title>
<source><![CDATA[Ann Neurol.]]></source>
<year>2008</year>
<volume>64</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>S101-10</page-range></nlm-citation>
</ref>
<ref id="B86">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PARDRIDGE]]></surname>
<given-names><![CDATA[W. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy]]></article-title>
<source><![CDATA[NeuroRx.]]></source>
<year>2005</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>129-38</page-range></nlm-citation>
</ref>
<ref id="B87">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PARDRIDGE]]></surname>
<given-names><![CDATA[W. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses]]></article-title>
<source><![CDATA[J. Control. Release]]></source>
<year>2007</year>
<volume>122</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>345-8</page-range></nlm-citation>
</ref>
<ref id="B88">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PEARSON]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[China approves first gene therapy]]></article-title>
<source><![CDATA[Nature Biotechnol.]]></source>
<year>2004</year>
<volume>22</volume>
<page-range>3-4</page-range></nlm-citation>
</ref>
<ref id="B89">
<nlm-citation citation-type="confpro">
<collab>PHACILITATE</collab>
<source><![CDATA[]]></source>
<year>Janu</year>
<month>ar</month>
<day>y,</day>
<conf-name><![CDATA[5 Annual Cell and Gene Therapy Forum]]></conf-name>
<conf-loc> </conf-loc>
<page-range>26-28</page-range><publisher-loc><![CDATA[Washington^eDC DC]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B90">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[POEHNER]]></surname>
<given-names><![CDATA[W. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A homozygous deletion in RPE65 in a small Sardinian family with autosomal recessive retinal dystrophy]]></article-title>
<source><![CDATA[Mol. Vis.]]></source>
<year>2000</year>
<volume>6</volume>
<page-range>192-8</page-range></nlm-citation>
</ref>
<ref id="B91">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[POEWE]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Treatments for Parkinson disease - past achievements and current clinical needs]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2009</year>
<volume>72</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>S65-73</page-range></nlm-citation>
</ref>
<ref id="B92">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PORTEUS]]></surname>
<given-names><![CDATA[M. H.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A look to future directions in gene therapy research for monogenic diseases]]></article-title>
<source><![CDATA[PLoS Genet.]]></source>
<year>2006</year>
<volume>2</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>e133</page-range></nlm-citation>
</ref>
<ref id="B93">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PROCHOWNIK]]></surname>
<given-names><![CDATA[E. V.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[c-Myc: linking transformation and genomic instability]]></article-title>
<source><![CDATA[Curr. Mol. Med.]]></source>
<year>2008</year>
<volume>8</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>446-58</page-range></nlm-citation>
</ref>
<ref id="B94">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RADUNOVIC]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Clinical care of patients with amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Lancet Neurol., v.6]]></source>
<year>2007</year>
<numero>10</numero>
<issue>10</issue>
<page-range>913-25</page-range></nlm-citation>
</ref>
<ref id="B95">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RAINOV]]></surname>
<given-names><![CDATA[N. G.]]></given-names>
</name>
<name>
<surname><![CDATA[REN]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene therapy for human malignant brain tumors]]></article-title>
<source><![CDATA[Cancer J.]]></source>
<year>2003</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>180-8</page-range></nlm-citation>
</ref>
<ref id="B96">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RAPER]]></surname>
<given-names><![CDATA[S. E.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer]]></article-title>
<source><![CDATA[Mol. Genet. Metab.]]></source>
<year>2003</year>
<volume>80</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>148-58</page-range></nlm-citation>
</ref>
<ref id="B97">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RAPER]]></surname>
<given-names><![CDATA[S. E.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency.]]></article-title>
<source><![CDATA[J. Inherit Metab. Dis.]]></source>
<year>1998</year>
<volume>21, Suppl. 1</volume>
<page-range>119-37</page-range></nlm-citation>
</ref>
<ref id="B98">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RÄTY]]></surname>
<given-names><![CDATA[J. K.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Improving safety of gene therapy]]></article-title>
<source><![CDATA[Curr. Drug Saf.]]></source>
<year>2008</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>46-53</page-range></nlm-citation>
</ref>
<ref id="B99">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[REFFELMANN]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy]]></article-title>
<source><![CDATA[J. Am. Coll. Cardiol.]]></source>
<year>2008</year>
<volume>53</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>305-8</page-range></nlm-citation>
</ref>
<ref id="B100">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[RIBACKA]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cancer, stem cells, and oncolytic viruses.]]></article-title>
<source><![CDATA[Ann. Med.]]></source>
<year>2008</year>
<volume>40</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>496-505</page-range></nlm-citation>
</ref>
<ref id="B101">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ROGERS]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[ROUS]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Joint action of a chemical carcinogen and a neoplastic virus to induce cancer in rabbits; results of exposing epidermal cells to a carcinogenic hydrocarbon at time of infection with the Shope papilloma virus]]></article-title>
<source><![CDATA[J. Exp. Med.]]></source>
<year>1951</year>
<volume>93</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>459-88</page-range></nlm-citation>
</ref>
<ref id="B102">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ROGERS]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Serial transplantation of rabbit papillomas caused by the Shope virus.]]></article-title>
<source><![CDATA[J. Exp. Med.]]></source>
<year>1952</year>
<volume>95</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>543-54</page-range></nlm-citation>
</ref>
<ref id="B103">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SANVICENS]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[MARCO]]></surname>
<given-names><![CDATA[M. P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Multifunctional nanoparticles--properties and prospects for their use in human medicine]]></article-title>
<source><![CDATA[Trends Biotechnol.]]></source>
<year>2008</year>
<volume>26</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>425-33</page-range></nlm-citation>
</ref>
<ref id="B104">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SCAGLIA]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[LEE]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency]]></article-title>
<source><![CDATA[Am. J. Med. Genet. C. Semin. Med. Genet.]]></source>
<year>2006</year>
<volume>142C</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>113-20</page-range></nlm-citation>
</ref>
<ref id="B105">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SILVA]]></surname>
<given-names><![CDATA[C. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Recent advances in DNA vaccines for autoimmune diseases]]></article-title>
<source><![CDATA[Expert Rev. Vaccines]]></source>
<year>2009</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>239-52</page-range></nlm-citation>
</ref>
<ref id="B106">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SYKES]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Progress in the development of genetic immunization]]></article-title>
<source><![CDATA[Expert Rev. Vaccines]]></source>
<year>2008</year>
<volume>7</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1395-404</page-range></nlm-citation>
</ref>
<ref id="B107">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[THAJEB]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The effects of storage conditions and trophic supplementation on the survival of fetal mesencephalic cells]]></article-title>
<source><![CDATA[Cell Transplant.]]></source>
<year>1997</year>
<volume>6</volume>
<page-range>297-307</page-range></nlm-citation>
</ref>
<ref id="B108">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TORRENTE]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[POLLI]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mesenchymal stem cell transplantation for neurodegenerative diseases]]></article-title>
<source><![CDATA[Cell Transplant.]]></source>
<year>2008</year>
<volume>17</volume>
<numero>10-11</numero>
<issue>10-11</issue>
<page-range>1103-13</page-range></nlm-citation>
</ref>
<ref id="B109">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van der SPUY]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Predominant rod photoreceptor degeneration in Leber congenital amaurosis]]></article-title>
<source><![CDATA[Mol Vis.]]></source>
<year>2005</year>
<volume>11</volume>
<page-range>542-53</page-range></nlm-citation>
</ref>
<ref id="B110">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[VAZQUEZ]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The genetics of the p53 pathway, apoptosis and cancer therapy]]></article-title>
<source><![CDATA[Nat. Rev. Drug Discov.]]></source>
<year>2008</year>
<volume>7</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>979-87</page-range></nlm-citation>
</ref>
<ref id="B111">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[VELLAI]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[VIDA]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The origin of eukaryotes: the difference between prokaryotic and eukaryotic cells]]></article-title>
<source><![CDATA[Proc. Biol. Sci.]]></source>
<year>1999</year>
<volume>266</volume>
<numero>1428</numero>
<issue>1428</issue>
<page-range>1571-7</page-range></nlm-citation>
</ref>
<ref id="B112">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[VENTER]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The sequence of the human genome.]]></article-title>
<source><![CDATA[Science]]></source>
<year>2001</year>
<volume>291</volume>
<numero>5507</numero>
<issue>5507</issue>
<page-range>1304-51</page-range></nlm-citation>
</ref>
<ref id="B113">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[VOSS]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Production of plasmid DNA for pharmaceutical use.]]></article-title>
<source><![CDATA[Biotechnol. Annu. Rev.]]></source>
<year>2007</year>
<volume>13</volume>
<page-range>201-22</page-range></nlm-citation>
</ref>
<ref id="B114">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WANG]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mitotic checkpoint defects in human cancers and their implications to chemotherapy]]></article-title>
<source><![CDATA[Front Biosci.]]></source>
<year>2008</year>
<volume>13</volume>
<page-range>2103-14</page-range></nlm-citation>
</ref>
<ref id="B115">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WATSON]]></surname>
<given-names><![CDATA[J. D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Recombinant DNA: genes and genomics: a short course]]></source>
<year>2006</year>
<publisher-loc><![CDATA[Freeman ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B116">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[WU]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[LU]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Inclusion of high molecular weight dextran in calcium phosphate-mediated transfection significantly improves gene transfer efficiency]]></article-title>
<source><![CDATA[Cell. Mol. Biol.]]></source>
<year>2007</year>
<volume>53</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>67-74</page-range><publisher-loc><![CDATA[Noisy-le-grand ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B117">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[YI]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[HAHM]]></surname>
<given-names><![CDATA[S. H.]]></given-names>
</name>
<name>
<surname><![CDATA[LEE]]></surname>
<given-names><![CDATA[K. H.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Retroviral gene therapy: safety issues and possible solutions]]></article-title>
<source><![CDATA[Curr. Gene Ther.]]></source>
<year>2005</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-35</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
